Medical Treatment ~ Ovarian Cancer
~ Genetics of Breast & Ovarian Cancer

Primarily chemotherapy, but includes all treatment modalities except surgery and radiation.

List was last updated on Dec 10, 2019 @ 7:31 am.


    • Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    • Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S.
    • Br J Cancer. 2019 Dec 9. doi: 10.1038/s41416-019-0674-4. [Epub ahead of print]
    • Mechanisms of PARP inhibitor resistance in ovarian cancer.
    • Kubalanza K, Konecny GE.
    • Curr Opin Obstet Gynecol. 2019 Dec 6. doi: 10.1097/GCO.0000000000000600. [Epub ahead of print]
    • Review
    • Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).
    • Palacios J, de la Hoya M, Bellosillo B, de Juan I, Matías-Guiu X, Lázaro C, Palanca S, Osorio A, Rojo F, Rosa-Rosa JM, Cigudosa JC.
    • Virchows Arch. 2019 Dec 3. doi: 10.1007/s00428-019-02709-3. [Epub ahead of print]
    • Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China.
    • Ni J, Cheng X, Zhou R, Xu X, Guo W, Chen X.
    • J Ovarian Res. 2019 Nov 28;12(1):117. doi: 10.1186/s13048-019-0594-1.
    • A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
    • Rettenmaier MA, Micha JP, Bohart R, Goldstein BH.
    • Eur J Obstet Gynecol Reprod Biol. 2019 Nov 9;244:101-105. doi: 10.1016/j.ejogrb.2019.10.047. [Epub ahead of print]
    • A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    • Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, Scalone S, Sorio R, Dreussi E, Zanusso C, De Mattia E, Roncato R, Cecchin E, Giorda G, De Vita S, Dal Bo M, Puglisi F, Toffoli G.
    • Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603-8. doi: 10.1016/j.ygyno.2019.10.019. [Epub ahead of print]
    • Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study.
    • Paik ES, Lee YJ, Lee JY, Shin W, Park SY, Kim SI, Kim JW, Choi CH, Kim BG.
    • J Clin Med. 2019 Nov 8;8(11). pii: E1920. doi: 10.3390/jcm8111920.
    • A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    • Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C.
    • Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569-0. doi: 10.1016/j.ygyno.2019.10.012. [Epub ahead of print]
    • Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    • Farolfi A, Lorusso D, Pignata S, De Giorgi U.
    • J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055. [Epub ahead of print]

    Original research:

    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

    • Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    • Sokolenko AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, Ivantsov AO, Iyevleva AG, Savonevich EL, Kotiv KB, Kuligina ES, Imyanitov EN.
    • Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776. [Epub ahead of print]
    • Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer.
    • [No author given.]
    • FORCE. XRAYS. 2019 Nov 5.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    • Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S.
    • Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607-5. doi: 10.1016/j.ygyno.2019.10.023. [Epub ahead of print]
    • Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
    • Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N.
    • J Ovarian Res. 2019 Nov 4;12(1):103. doi: 10.1186/s13048-019-0579-0.
    • Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.
    • Mariniello A, Ghisoni E, Righi L, Catino A, Chiari R, Del Conte A, Barbieri F, Cecere F, Gelibter A, Giajlevra M, Parra HS, Zichi C, DI Maio M, Valabrega G, Novello S.
    • In Vivo. 2019 Nov-Dec;33(6):2021-2026. doi: 10.21873/invivo.11699.
    • Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
    • Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.
    • Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.
    • Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    • Xu L, Wu Y, Che X, Zhao J, Wang F, Wang P, Qu X, Liu Y, Li Z.
    • DNA Cell Biol. 2019 Oct 29. doi: 10.1089/dna.2019.4826. [Epub ahead of print]
    • FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers.
    • Ray T.
    • GenomeWeb. 2019 Oct 29.
    • Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
    • Fumagalli C, Tomao F, Betella I, Rappa A, Calvello M, Bonanni B, Bernard L, Peccatori F, Colombo N, Viale G, Barberis M, Guerini-Rocco E.
    • Cancers (Basel). 2019 Oct 24;11(11). pii: E1641. doi: 10.3390/cancers11111641.
    • Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
    • Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, Ryan JE, Sheriff M, Rassy E, Pavlidis N.
    • Invest New Drugs. 2019 Oct 24. doi: 10.1007/s10637-019-00867-4. [Epub ahead of print]
    • Review
    • FDA Approves GSK's Zejula Alongside Myriad Genetics CDx for Advanced Ovarian Cancer.
    • [No author given]
    • GenomeWeb. 2019 Oct 23.
    • A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    • Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A.
    • Am J Surg Pathol. 2019 Oct 22. doi: 10.1097/PAS.0000000000001391. [Epub ahead of print]
    • Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    • Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.
    • Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]
    • Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    • Veneris JT, Matulonis UA, Liu JF, Konstantinopoulos PA.
    • Gynecol Oncol. 2019 Oct 17. pii: S0090-8258(19)31549-5. doi: 10.1016/j.ygyno.2019.09.021. [Epub ahead of print]
    • Review
    • PARP Inhibition in Cancer: An Update on Clinical Development.
    • Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.
    • Target Oncol. 2019 Oct 17. doi: 10.1007/s11523-019-00680-2. [Epub ahead of print]
    • Review
    • Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
    • Page CL, Chung J, Rahimi K, Kobel M, Provencher D, Masson AMM.
    • Curr Drug Targets. 2019 Oct 16. doi: 10.2174/1389450120666191016143836. [Epub ahead of print]
    • Review
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    • Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB.
    • Cancer Treat Rev. 2019 Oct 9;80:101909. doi: 10.1016/j.ctrv.2019.101909. [Epub ahead of print]
    • Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    • Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545-8. doi: 10.1016/j.ygyno.2019.09.020. [Epub ahead of print]
    • Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    • Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I.
    • Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528-8. doi: 10.1016/j.ygyno.2019.09.008. [Epub ahead of print]
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Success for First-Line PARP Inhibition in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 7. doi: 10.1158/2159-8290.CD-NB2019-121. [Epub ahead of print]
    • News
    • PARP Inhibitors Center Stage for Ovarian Cancer — PRIMA, PAOLA-1, and VELIA Trials
    • Banerjee SN.
    • Medscape Oncology. 2019 Oct 7.
    • Who Should Consider Genetic Counseling and Testing for Breast and Ovarian Cancer? Guidelines Have Expanded.
    • [No author given]
    • My Gene Counsel. 2019 Oct 3.
    • Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
    • Curtin NJ, Drew Y, Sharma-Saha S.
    • Nat Rev Clin Oncol. 2019 Oct 3. doi: 10.1038/s41571-019-0285-2. [Epub ahead of print]
    • Commentary
    • Genetic testing in ovarian cancer - clinical impact and current practices.
    • Knabben L, Imboden S, Mueller MD.
    • Horm Mol Biol Clin Investig. 2019 Oct 2. pii: /j/hmbci.ahead-of-print/hmbci-2019-0025/hmbci-2019-0025.xml. doi: 10.1515/hmbci-2019-0025. [Epub ahead of print]
    • Review
    • Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
    • Cybulska P, Hayes SA, Spirtos A, Rafizadeh MJ, Filippova OT, Leitao M, Zivanovic O, Sonoda Y, Mueller J, Lakhman Y, Long K, Chi DS.
    • Int J Gynecol Cancer. 2019 Oct 1. pii: ijgc-2019-000829. doi: 10.1136/ijgc-2019-000829. [Epub ahead of print]
    • Niraparib - A promising drug with hematological toxicity.
    • Patibandla NS, Monga DK.
    • J Oncol Pharm Pract. 2019 Oct;25(7):1749-1753. doi: 10.1177/1078155218800156. Epub 2018 Oct 6.
    • Case report
    • Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
    • Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • Yonsei Med J. 2019 Oct;60(10):914-923. doi: 10.3349/ymj.2019.60.10.914.
    • PARP Inhibitors Move Into First-Line for Ovarian Cancer.
    • Chustecka Z.
    • Medscape Oncology. 2019 Sep 29.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
    • Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.
    • N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1909707. [Epub ahead of print]
    • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.
    • N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910962. [Epub ahead of print]

    Research news: Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer. (FORCE. XRAYS.)

    • The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers.
    • Ismael M, Webb R, Ajaz M, Kirkby KJ, Coley HM.
    • Cancers (Basel). 2019 Sep 25;11(10). pii: E1429. doi: 10.3390/cancers11101429.
    • Advances in the treatment of ovarian cancer using PARP inhibitors and the underlying mechanism of resistance.
    • Wang L, Wang Q, Xu Y, Han L.
    • Curr Drug Targets. 2019 Sep 25. doi: 10.2174/1389450120666190925123507. [Epub ahead of print]
    • Review
    • Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    • Poveda AM, Davidson R, Blakeley C, Milner A.
    • Future Oncol. 2019 Sep 25. doi: 10.2217/fon-2019-0343. [Epub ahead of print]
    • Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
    • Pietragalla A, Minucci A, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Sep 19. pii: ijgc-2019-000757. doi: 10.1136/ijgc-2019-000757. [Epub ahead of print]
    • ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
    • Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.
    • Mol Cancer Ther. 2019 Sep 18. pii: molcanther.0242.2019. doi: 10.1158/1535-7163.MCT-19-0242. [Epub ahead of print]
    • Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    • Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR.
    • J Clin Oncol. 2019 Sep 16:JCO1900917. doi: 10.1200/JCO.19.00917. [Epub ahead of print]
    • Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
    • Yu Y, Durairaj C, Shi H, Wang DD.
    • J Clin Pharmacol. 2019 Sep 6. doi: 10.1002/jcph.1520. [Epub ahead of print]
    • Olaparib in the treatment of ovarian cancer.
    • Washington CR, Richardson DL, Moore KN.
    • Future Oncol. 2019 Sep 3. doi: 10.2217/fon-2019-0271. [Epub ahead of print]
    • Review
    • Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    • Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, You D, Yi T, Wang P, Zhao X.
    • Int J Cancer. 2019 Sep 1;145(5):1209-1220. doi: 10.1002/ijc.32143. Epub 2019 Feb 23.
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
    • Mukhopadhyay A, Drew Y, Matheson E, Salehan M, Gentles L, Pachter JA, Curtin NJ.
    • Biochem Pharmacol. 2019 Sep;167:125-132. doi: 10.1016/j.bcp.2018.10.011. Epub 2018 Oct 17.
    • Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases.
    • Gray S, Khor XY, Yiannakis D.
    • BMJ Case Rep. 2019 Aug 28;12(8). pii: e230738. doi: 10.1136/bcr-2019-230738.
    • Case report
    • Hopes and failures in front-line ovarian cancer therapy.
    • Tsibulak I, Zeimet AG, Marth C.
    • Crit Rev Oncol Hematol. 2019 Aug 14;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. [Epub ahead of print]
    • The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination deficient- and Schlafen 11-positive cancer cells and synergize with olaparib.
    • Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0419.2019. doi: 10.1158/1078-0432.CCR-19-0419. [Epub ahead of print]
    • The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP inhibition.
    • Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0448.2019. doi: 10.1158/1078-0432.CCR-19-0448. [Epub ahead of print]
    • Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations.
    • Jorge S, Swisher EM, Norquist BM, Pennington KP, Gray HJ, Urban RR, Garcia RL, Doll KM.
    • Gynecol Oncol Rep. 2019 Aug 9;29:113-117. doi: 10.1016/j.gore.2019.08.001. eCollection 2019 Aug.
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    • Mirza MR, Bergmann TK, Mau-Sørensen M, Christensen RD, Åvall-Lundqvist E, Birrer MJ, Jørgensen M, Roed H, Malander S, Nielsen F, Lassen U, Brøsen K, Bjørge L, Mäenpää J.
    • Cancer Chemother Pharmacol. 2019 Aug 2. doi: 10.1007/s00280-019-03917-z. [Epub ahead of print]
    • Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
    • Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • Diagnostics (Basel). 2019 Aug 1;9(3). pii: E87. doi: 10.3390/diagnostics9030087.
    • Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group.
    • Lai CH, Vallikad E, Lin H, Yang LY, Jung SM, Liu HE, Ou YC, Chou HH, Lin CT, Huang HJ, Huang KG, Qiu J, Hung YC, Wu TI, Chang WY, Tan KT, Lin CY, Chao A, Chang CJ.
    • J Gynecol Oncol. 2019 Jul 26. doi: 10.3802/jgo.2020.31.e5. [Epub ahead of print]
    • Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy.
    • Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L.
    • Oncologist. 2019 Jul 25. pii: theoncologist.2019-0272. doi: 10.1634/theoncologist.2019-0272. [Epub ahead of print]
    • GSK Drug Helps Ovarian Cancer Patients Live Longer in Late-Stage Study.
    • Zainab Hussain N, Aripaka P.
    • Medscape Oncology. 2019 Jul 18.
    • Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
    • Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ1, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.
    • Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.
    • Conference report, Commentary
    • Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    • Armstrong AC, Clay V.
    • Future Oncol. 2019 Jul 15. doi: 10.2217/fon-2018-0067. [Epub ahead of print]
    • Review
    • Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    • Vanacker H, Romeo C, Ray-Coquard I.
    • Curr Opin Oncol. 2019 Jul 10. doi: 10.1097/CCO.0000000000000557. [Epub ahead of print]
    • Review
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.
    • Ashour M, Ezzat Shafik H.
    • Cancer Manag Res. 2019 Jul 8;11:6275-6284. doi: 10.2147/CMAR.S206817. eCollection 2019.
    • FoundationOne CDx Approved as Companion Diagnostic to Lynparza in Ovarian Cancer.
    • [No author given.]
    • Clinical Omics. 2019 Jul 3.
    • The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
    • Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P.
    • J BUON. 2019 Jul-Aug;24(4):1538-1543.
    • The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report.
    • Yim GW, Suh DH, Kim JW, Kim SC, Kim YT.
    • J Gynecol Oncol. 2019 Jul;30(4):e91. doi: 10.3802/jgo.2019.30.e91.
    • Fallopian Tube Carcinoma.
    • Stasenko M, Fillipova O, Tew WP.
    • J Oncol Pract. 2019 Jul;15(7):375-382. doi: 10.1200/JOP.18.00662. Epub 2019 Jul 8.

    Commentary:

    Rapidly Changing Landscape of Fallopian Tube Carcinoma.

    • Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2019 Jun 21.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Jun 20. pii: mdz192. doi: 10.1093/annonc/mdz192. [Epub ahead of print]
    • AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    • Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.
    • J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009. [Epub ahead of print]

    Letter, Commentary:

    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.

    • European Commission Approves Lynparza for Advanced Ovarian Cancer With BRCA Mutations.
    • [No author given]
    • Precision Oncology News (GenomeWeb). 2019 Jun 18.
    • Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
    • Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
    • Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F.
    • Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1.
    • Clinical Impact of RANK Signalling in Ovarian Cancer.
    • Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.
    • Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.
    • Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    • Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR.
    • J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238. [Epub ahead of print]
    • High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    • Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.
    • Cancer. 2019 Jun 2. doi: 10.1002/cncr.32079. [Epub ahead of print]

    Commentary:

    Clarifying the role of EMSY in DNA repair in ovarian cancer

    • PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    • Cook SA, Tinker AV.
    • BioDrugs. 2019 Jun;33(3):255-273. doi: 10.1007/s40259-019-00347-4.
    • Review
    • Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    • Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacol Ther. 2019 Jun;105(6):1492-1500. doi: 10.1002/cpt.1338. Epub 2019 Feb 22.
    • Review
    • Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    • Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK.
    • Gynecol Oncol. 2019 Jun;153(3):568-573. doi: 10.1016/j.ygyno.2019.03.004. Epub 2019 Mar 12.
    • Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
    • Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
    • Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
    • Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.
    • Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.
    • Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.
    • Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    • Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.
    • Crit Rev Oncol Hematol. 2019 May 25;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. [Epub ahead of print]
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 May 24. pii: e9982. doi: 10.15252/emmm.201809982. [Epub ahead of print]
    • Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    • Ledermann JA, Pujade-Lauraine E.
    • Ther Adv Med Oncol. 2019 May 22;11:1758835919849753. doi: 10.1177/1758835919849753. eCollection 2019.
    • Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    • Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CR Collaborative Network (Supplementary 1), Singh N.
    • Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181-3. doi: 10.1016/j.ygyno.2019.04.679. [Epub ahead of print]
    • PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
    • Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N.
    • Diagnostics (Basel). 2019 May 18;9(2). pii: E55. doi: 10.3390/diagnostics9020055.
    • Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
    • Lheureux S, Braunstein M, Oza AM.
    • CA Cancer J Clin. 2019 May 17. doi: 10.3322/caac.21559. [Epub ahead of print]
    • [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
    • Nikolopoulou A, Galli-Vareia I, Stravodimou A, Sarivalasis A, Zaman K.
    • Rev Med Suisse. 2019 May 15;15(651):1027-1031.
    • Review, [Article in French]
    • Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.
    • Eskilera GG, Cecener G, Dikmen G, Egeli U, Tunca B.
    • Curr Drug Deliv. 2019 May 14. doi: 10.2174/1567201816666190515105532. [Epub ahead of print]
    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
    • Jiang X, Li W, Li X, Bai H, Zhang Z.
    • Cancer Manag Res. 2019 May 10;11:4371-4390. doi: 10.2147/CMAR.S200524. eCollection 2019.
    • Biomarkers of drug resistance in ovarian cancer - an update.
    • Davidson B.
    • Expert Rev Mol Diagn. 2019 May 10. doi: 10.1080/14737159.2019.1618187. [Epub ahead of print]
    • Review
    • Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.
    • Baldwin P, Ohman AW, Medina JE, McCarthy ET, Dinulescu DM, Sridhar S.
    • Front Oncol. 2019 May 10;9:353. doi: 10.3389/fonc.2019.00353. eCollection 2019.
    • Veliparib: a new therapeutic option in ovarian cancer?
    • Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G.
    • Future Oncol. 2019 May 10. doi: 10.2217/fon-2018-0883. [Epub ahead of print]
    • Review
    • Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    • Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P.
    • Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504-9. doi: 10.1016/j.ygyno.2019.04.009. [Epub ahead of print]
    • Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
    • Pan K, Gong J, Huynh K, Cristea M.
    • Target Oncol. 2019 May 8. doi: 10.1007/s11523-019-00641-9. [Epub ahead of print]
    • Review
    • Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    • Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    • J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7.
    • Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    • da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR.
    • BMC Cancer. 2019 May 6;19(1):422. doi: 10.1186/s12885-019-5622-4.
    • Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
    • Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacokinet. 2019 May;58(5):615-625. doi: 10.1007/s40262-018-0714-x.
    • Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    • Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, Pennington KP, Garcia RL, Liao JB, Swisher EM.
    • Gynecol Oncol. 2019 May;153(2):217-222. doi: 10.1016/j.ygyno.2019.02.011. Epub 2019 Feb 23.

    Editorial:

    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?

    • ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    • Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.
    • Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 20.
    • Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
    • Naumann RW, Coleman RL, Brown J, Moore KN.
    • Gynecol Oncol. 2019 May;153(2):436-444. doi: 10.1016/j.ygyno.2019.02.008. Epub 2019 Feb 12.
    • Review
    • BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    • Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E.
    • Int J Gynecol Cancer. 2019 May;29(4):779-786. doi: 10.1136/ijgc-2018-000175. Epub 2019 Mar 5.
    • Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
    • Miller RE, Crusz SM, Ledermann JA.
    • Future Oncol. 2019 Apr 30. doi: 10.2217/fon-2019-0057. [Epub ahead of print]
    • Review
    • Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
    • Macedo GS, Alemar B, Ashton-Prolla P.
    • Genet Mol Biol. 2019 Apr 29. pii: S1415-47572019005015101. doi: 10.1590/1678-4685-GMB-2018-0104. [Epub ahead of print]
    • Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
    • Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.
    • Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.
    • Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.
    • Liu L, Liu P, Liang Z, Li R, Shen M, Xu H, Ren D, Ji M, Yang Y, Lu Z, Shang D, Zhang Y, Liu H, Tu Z.
    • Anticancer Drugs. 2019 Apr 16. doi: 10.1097/CAD.0000000000000793. [Epub ahead of print]
    • Review
    • Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials.
    • Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X.
    • Cancer Manag Res. 2019 Apr 16;11:3061-3078. doi: 10.2147/CMAR.S191107. eCollection 2019.
    • Detecting the mutational signature of homologous recombination deficiency in clinical samples.
    • Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.
    • Nat Genet. 2019 Apr 15. doi: 10.1038/s41588-019-0390-2. [Epub ahead of print]
    • Rucaparib in the landscape of PARP inhibition in ovarian cancer.
    • Colomba E, Pautier P, Pommeret F, Leary A.
    • Expert Rev Anticancer Ther. 2019 Apr 12. doi: 10.1080/14737140.2019.1607302. [Epub ahead of print]
    • Review
    • N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance.
    • Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R.
    • Cancer Res. 2019 Apr 9. pii: canres.3592.2018. doi: 10.1158/0008-5472.CAN-18-3592. [Epub ahead of print]
    • Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
    • Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O’Connor MJ, Clarke AR, Smalley MJ.
    • Oncotarget. 2019 Apr 5;10(27):2586-2606. doi: 10.18632/oncotarget.26830. eCollection 2019 Apr 5.
    • Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    • Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA.
    • Ann Oncol. 2019 Apr 1;30(4):551-557. doi: 10.1093/annonc/mdz018.
    • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    • Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.
    • Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30029-4. doi: 10.1016/S1470-2045(19)30029-4. [Epub ahead of print]

    Commentary:

    Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?

    • 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    • Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.
    • Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.
    • PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    • Jiang X, Li X, Li W, Bai H, Zhang Z.
    • J Cell Mol Med. 2019 Apr;23(4):2303-2313. doi: 10.1111/jcmm.14133. Epub 2019 Jan 22.
    • Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
    • Moore DC, Ringley JT, Patel J.
    • J Pharm Pract. 2019 Apr;32(2):219-224. doi: 10.1177/0897190017743131. Epub 2017 Nov 22.
    • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    • Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

    Commentary:

    Extending the scope of PARP inhibitors in ovarian cancer.

    • U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    • Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ.
    • Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.
    • Rucaparib: A Review in Ovarian Cancer.
    • Shirley M.
    • Target Oncol. 2019 Apr;14(2):237-246. doi: 10.1007/s11523-019-00629-5.
    • Review
    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition.
    • Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.
    • Mol Cancer Ther. 2019 Mar 29. pii: molcanther.0770.2018. doi: 10.1158/1535-7163.MCT-18-0770. [Epub ahead of print]
    • Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    • McCann KE.
    • Future Oncol. 2019 Mar 26. doi: 10.2217/fon-2018-0751. [Epub ahead of print]
    • Review
    • Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
    • Madariaga A, Lheureux S, Oza AM.
    • Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416.
    • Epithelial ovarian cancer.
    • Lheureux S, Gourley C, Vergote I, Oza AM.
    • Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.
    • Review
    • DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    • Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS.
    • Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
    • TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer.
    • Harrison P.
    • Medscape Oncology. Conference News. 2019 Mar 18.
    • Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.
    • Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL.
    • Cancers (Basel). 2019 Mar 13;11(3). pii: E354. doi: 10.3390/cancers11030354.
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors.
    • Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.
    • Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    • Foote JR, Secord AA, Liang MI, Ehrisman JA, Cohn DE, Jewell E, Havrilesky LJ.
    • Gynecol Oncol. 2019 Mar;152(3):445-451. doi: 10.1016/j.ygyno.2018.11.028.
    • Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    • Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA.
    • Gynecol Oncol. 2019 Mar;152(3):560-567. doi: 10.1016/j.ygyno.2018.12.009. Epub 2019 Jan 9.
    • PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    • Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.
    • J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.
    • Review
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
    • Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L.
    • J Med Genet. 2019 Mar;56(3):195-198. doi: 10.1136/jmedgenet-2017-105140. Epub 2018 Mar 13.
    • Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
    • Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis AM, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Buettner R, Schweiger MR.
    • J Mol Diagn. 2019 Mar;21(2):198-213. doi: 10.1016/j.jmoldx.2018.10.007. Epub 2018 Dec 19.
    • Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.
    • Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M.
    • J Obstet Gynaecol Res. 2019 Mar;45(3):743-747. doi: 10.1111/jog.13851. Epub 2018 Nov 22.
    • Case report
    • Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
    • Guy H, Walder L, Fisher M.
    • Pharmacoeconomics. 2019 Mar;37(3):391-405. doi: 10.1007/s40273-018-0745-z.
  1. s
    • High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    • Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
    • Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.
    • Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
    • Murthy P, Muggia F.
    • Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019.
    • Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    • Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.
    • Exaggeration of PFS by blinded, independent, central review (BICR).
    • Stone A, Gebski V, Davidson R, Bloomfield R, Bartlett JW, Sabin A.
    • Ann Oncol. 2019 Feb 1;30(2):332-338. doi: 10.1093/annonc/mdy514.
    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    • Velázquez C, Esteban-Cardeñosa EM, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Durán M, Infante M.
    • Breast. 2019 Feb;43:91-96. doi: 10.1016/j.breast.2018.11.010. Epub 2018 Nov 29.
    • Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    • Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M.
    • Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17.
    • BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
    • Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.
    • Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.
    • Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    • Washington C, Gunderson CC, Moore KN.
    • Curr Opin Obstet Gynecol. 2019 Feb;31(1):4-11. doi: 10.1097/GCO.0000000000000507.
    • Review
    • Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
    • McCann KE.
    • Curr Opin Obstet Gynecol. 2019 Feb;31(1):12-17. doi: 10.1097/GCO.0000000000000517.
    • Review
    • [Part II drafted from the short text of the French guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly, fertility preservation, follow-up)].
    • Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.
    • Gynecol Obstet Fertil Senol. 2019 Feb;47(2):111-119. doi: 10.1016/j.gofs.2018.12.011. Epub 2019 Jan 28.
    • Review, [Article in French]
    • [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    • de la Motte Rouge T, Ray-Coquard I, You B.
    • Gynecol Obstet Fertil Senol. 2019 Feb;47(2):222-237. doi: 10.1016/j.gofs.2019.01.002. Epub 2019 Jan 29.
    • Review, [Article in French]
    • Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    • Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dientsmann R, Oaknin A.
    • Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12.
    • Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    • Mullen MM, Kuroki LM, Thaker PH.
    • Gynecol Oncol. 2019 Feb;152(2):416-425. doi: 10.1016/j.ygyno.2018.10.023. Epub 2018 Nov 5.
    • Review
    • Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    • Wu L, Zhong L.
    • J Med Econ. 2019 Feb;22(2):187-195. doi: 10.1080/13696998.2018.1557199. Epub 2019 Jan 4.
    • PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
    • Bellio C, DiGloria C, Foster R, James K, Konstantinopoulos PA, Growdon WB, Rueda BR.
    • Mol Cancer Res. 2019 Feb;17(2):431-445. doi: 10.1158/1541-7786.MCR-18-0594. Epub 2018 Nov 6.
    • Olaparib: A tale of two dosage forms.
    • Christ TN.
    • Semin Oncol. 2019 Feb;46(1):100-101. doi: 10.1053/j.seminoncol.2018.11.003. Epub 2018 Dec 19.
    • Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
    • Rivkin SE, Moon J, Iriarte DS, Bailey E, Sloan HL, Goodman GE, BonDurant AE, Velijovich D, Wahl T, Jiang P, Shah CA, Drescher C, Fer MF, Kaplan HG, Ellis ED.
    • Int J Gynecol Cancer. 2019 Jan 29. pii: ijgc-2018-000035. doi: 10.1136/ijgc-2018-000035. [Epub ahead of print]
    • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    • Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    • J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
    • Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    • Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH.
    • BMC Cancer. 2019 Jan 10;19(1):44. doi: 10.1186/s12885-018-5250-4.
    • GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
    • Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, Gonzalez-Martin A.
    • Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107. eCollection 2019 Feb.
    • Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    • Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.
    • Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24.
    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
    • Matthews Hew T, Zuberi L.
    • J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619864989. doi: 10.1177/2324709619864989.
    • The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    • Yap TA, Plummer R, Azad NS, Helleday T.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):185-195. doi: 10.1200/EDBK_238473.
    • The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer.
    • Monk BJ, Randall LM, Grisham RN.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):e141-e151. doi: 10.1200/EDBK_239007.
    • Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    • Chartron E, Theillet C, Guiu S, Jacot W.
    • Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5.
    • Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    • Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H.
    • Gynecol Oncol. 2019 Jan;152(1):157-165. doi: 10.1016/j.ygyno.2018.10.027. Epub 2018 Nov 7.
    • The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    • Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.
    • Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
    • Exploring and comparing adverse events between PARP inhibitors.
    • LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
    • Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.
    • Review
    • Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    • Li N, Wang Y, Deng W, Lin SH.
    • Anticancer Agents Med Chem. 2019;19(2):206-212. doi: 10.2174/1871520618666181109164645.
    • Review
    • DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
    • López-Camarillo C, Rincón DG, Ruiz-García E, Astudillo-de la Vega H, Marchat LA.
    • Curr Protein Pept Sci. 2019;20(4):316-323. doi: 10.2174/1389203719666180914091537.
    • Review
    • Experiencia con el uso de olaparib en pacientes con cáncer de ovario.
    • Gallardo-Rincón D, Alamilla-García G, Montes-Servín E, Morales-Vázquez F, Cano-Blanco C, Coronel-Martínez J, Bahena-González A, Gerson-Cwilich R, Isla-Ortiz D, Toledo-Leyva A, Montes-Servín E, Michel-Tello D, Espinosa-Romero R.
    • Gac Med Mex. 2019;155(6):585-589. doi: 10.24875/GMM.19005494.
    • Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
    • Kowalik A, Zalewski K, Kopczyński J, Siołek M, Lech M, Hińcza K, Kalisz J, Chrapek M, Zięba S, Furmańczyk J, Jedliński M, Chłopek M, Misiek M, Góźdź S.
    • Pol J Pathol. 2019;70(2):115-126. doi: 10.5114/pjp.2019.82905.
    • Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
    • N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.

    Editorial:

    Progress in BRCA-Mutated Ovarian Cancer.

    • USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    • Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D, Parmar K, Yusufzai T, Zheng N, D'Andrea AD.
    • Mol Cell. 2018 Dec 20;72(6):925-941.e4. doi: 10.1016/j.molcel.2018.10.045.
    • PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
    • Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ.
    • Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
    • Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    • Faraoni I, Graziani G.
    • Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487.
    • Principles of clinical management of ovarian cancer.
    • Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyanitov EN.
    • Chin Clin Oncol. 2018 Dec;7(6):56. doi: 10.21037/cco.2018.10.06.
    • How safe is rucaparib in ovarian cancer?
    • Cosgrove CM, O'Malley DM.
    • Expert Opin Drug Saf. 2018 Dec;17(12):1249-1255. doi: 10.1080/14740338.2018.1550067. Epub 2018 Dec 11.
    • Review
    • Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
    • Dal Molin GZ, Westin SN, Coleman RL.
    • Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14.
    • Review
    • Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    • Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, Amacker-North L, Templin M, Brown J.
    • Gynecol Oncol. 2018 Dec;151(3):477-480. doi: 10.1016/j.ygyno.2018.10.003. Epub 2018 Oct 8.
    • Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.
    • Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, Weber-Lassalle N, Prieske K, Dietrich D, Borde J, Pohl-Rescigno E, Reuss A, Ataseven B, Engel C, Stingl JC, Schmutzler RK, Hahnen E.
    • Hum Mutat. 2018 Dec;39(12):2040-2046. doi: 10.1002/humu.23653. Epub 2018 Oct 3.
    • Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
    • Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES.
    • J Cancer Res Clin Oncol. 2018 Dec;144(12):2449-2456. doi: 10.1007/s00432-018-2753-y. Epub 2018 Sep 25.
    • Maintenance olaparib in advanced ovarian cancer.
    • Burki TK.
    • Lancet Oncol. 2018 Dec;19(12):e671. doi: 10.1016/S1470-2045(18)30816-7. Epub 2018 Oct 25.
    • Research news
    • Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study.
    • Eriksson I, Wettermark B, Bergfeldt K.
    • Target Oncol. 2018 Dec;13(6):725-733. doi: 10.1007/s11523-018-0604-z.
    • Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
    • Heo YA, Dhillon S.
    • Target Oncol. 2018 Dec;13(6):801-808. doi: 10.1007/s11523-018-0606-x.
    • Review
    • Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.
    • Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S.
    • Int J Nanomedicine. 2018 Nov 29;13:8063-8074. doi: 10.2147/IJN.S186881. eCollection 2018.
    • Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    • Kurnit KC, Coleman RL, Westin SN.
    • Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7.
    • Review
    • Review of Immune Therapies Targeting Ovarian Cancer.
    • Fan CA, Reader J, Roque DM.
    • Curr Treat Options Oncol. 2018 Nov 14;19(12):74. doi: 10.1007/s11864-018-0584-3.
    • Review
    • Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.
    • Pearre DC, Tewari KS.
    • Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018.
    • Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
    • Burgess BT, Kolesar JM.
    • Am J Health Syst Pharm. 2018 Nov 1;75(21):1697-1707. doi: 10.2146/ajhp180124. Epub 2018 Sep 18.
    • Review
    • Secondary cytoreduction in ovarian cancer: who really benefits?
    • Giudice MT, D'Indinosante M, Cappuccio S, Gallotta V, Fagotti A, Scambia G, Petrillo M.
    • Arch Gynecol Obstet. 2018 Nov;298(5):873-879. doi: 10.1007/s00404-018-4915-1. Epub 2018 Sep 25.
    • Review
    • Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    • Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.
    • Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.
    • The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
    • Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.
    • Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3.
    • Mechanisms of PARP inhibitor sensitivity and resistance.
    • D'Andrea AD.
    • DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23.
    • Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.
    • Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M.
    • Eur Radiol. 2018 Nov;28(11):4849-4859. doi: 10.1007/s00330-018-5389-z. Epub 2018 May 8.
    • A Case of Immune-Mediated Liver Injury Induced by Olaparib.
    • Tufoni M, Serena Ricci C, Zaccherini G.
    • Hepatology. 2018 Nov;68(5):2039-2041. doi: 10.1002/hep.30119. Epub 2018 Oct 13.
    • Case report
    • Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
    • Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J.
    • J Gynecol Oncol. 2018 Nov;29(6):e93. doi: 10.3802/jgo.2018.29.e93.
    • Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.
    • Harold JA, Free SC, Bradley WH.
    • Gynecol Oncol Rep. 2018 Oct 28;26:91-93. doi: 10.1016/j.gore.2018.10.011. eCollection 2018 Nov.
    • Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.
    • Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R.
    • Int J Mol Sci. 2018 Oct 19;19(10). pii: E3249. doi: 10.3390/ijms19103249.
    • Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    • Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.
    • Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.
    • Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    • Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J.
    • Br J Cancer. 2018 Oct;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y. Epub 2018 Oct 24.

    Press: 'Outstanding' Ovarian Cancer PFS With Olaparib Maintenance. (Medscape Oncology)

    • Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    • Stewart J, George A, Banerjee S.
    • Expert Rev Anticancer Ther. 2018 Oct;18(10):947-958. doi: 10.1080/14737140.2018.1510323. Epub 2018 Aug 24.
    • Review
    • The role of niraparib for the treatment of ovarian cancer.
    • Ethier JL, Lheureux S, Oza AM.
    • Future Oncol. 2018 Oct;14(25):2565-2577. doi: 10.2217/fon-2018-0101. Epub 2018 Jun 1.
    • Review
    • Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
    • Gorodnova TV, Kotiv KB, Ivantsov AO, Mikheyeva ON, Mikhailiuk GI, Lisyanskaya AS, Mikaya NA, Guseynov KD, Bondarev NE, Matveyeva NS, Nekrasova EA, Sidoruk AA, Roman LD, Manikhas GM, Belyaev AM, Sokolenko AP, Berlev IV, Imyanitov EN.
    • Int J Gynecol Cancer. 2018 Oct;28(8):1498-1506. doi: 10.1097/IGC.0000000000001352.
    • A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    • van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.
    • Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.
    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
    • Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.
    • Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.
    • Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
    • Clements KE, Thakar T, Nicolae CM, Liang X, Wang HG, Moldovan GL.
    • Nucleic Acids Res. 2018 Sep 28;46(17):8898-8907. doi: 10.1093/nar/gky657.
    • Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer.
    • Filipi JG, Penson RT.
    • NCCN Continuing Education. 2018 Sep 25.
    • A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    • Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.
    • Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.
    • Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.
    • Shen JP, Ideker T.
    • J Mol Biol. 2018 Sep 14;430(18 Pt A):2900-2912. doi: 10.1016/j.jmb.2018.06.026. Epub 2018 Jun 20.
    • Role of PARP Inhibitors in BRCA-Related Malignancies.
    • Iqbal S, Rattu MA, Shah N.
    • US Pharm. 2018 Sep 14;9(43):HS10-HS16
    • PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
    • Konstantinopoulos PA, Matulonis UA.
    • Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.
    • Commentary, Review

    Review:

    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.

    • FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    • Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.
    • Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.
    • Review

    Commentary, Review:

    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.

    • BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    • Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.
    • Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.
    • Inherited gynaecological cancers.
    • George A.
    • Curr Opin Oncol. 2018 Sep;30(5):317-322. doi: 10.1097/CCO.0000000000000465.
    • Review
    • Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    • Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C.
    • Gynecol Oncol. 2018 Sep;150(3):534-544. doi: 10.1016/j.ygyno.2018.07.002. Epub 2018 Jul 17.
    • Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
    • McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice.
    • J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24.
    • Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
    • Ringley JT, Moore DC, Patel J, Rose MS.
    • P T. 2018 Sep;43(9):549-556.
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    • Cardoso FC, Goncalves S, Mele PG, Liria NC, Sganga L, Diaz Perez I, Podesta EJ, Solano AR.
    • Hum Genomics. 2018 Aug 13;12(1):39. doi: 10.1186/s40246-018-0171-5.
    • The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
    • Guo XX, Wu HL, Shi HY, Su L, Zhang X.
    • Cancer Manag Res. 2018 Aug 10;10:2553-2562. doi: 10.2147/CMAR.S169558. eCollection 2018.
    • Safety and dose modification for patients receiving niraparib.
    • Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.
    • Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di LJ.
    • Clin Cancer Res. 2018 Aug 1;24(15):3560-3571. doi: 10.1158/1078-0432.CCR-17-3862. Epub 2018 Apr 16.
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    • Ventriglia J, Paciolla I, Cecere SC, Pisano C, Di Napoli M, Arenare L, Setola SV, Losito NS, Califano D, Orditura M, Pignata S.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):498-503. doi: 10.1016/j.clon.2018.01.008. Epub 2018 Feb 9.
    • Review
    • Niraparib for the treatment of ovarian cancer.
    • Essel KG, Moore KN.
    • Expert Rev Anticancer Ther. 2018 Aug;18(8):727-733. doi: 10.1080/14737140.2018.1490180. Epub 2018 Jul 2.
    • Review
    • Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    • Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.
    • Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17.

    Research news:

    PARP inhibitors and quality of life in ovarian cancer.

    • Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
    • Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E.
    • Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17.

    Research news:

    PARP inhibitors and quality of life in ovarian cancer.

    • Niraparib: A Review in Ovarian Cancer.
    • Heo YA, Duggan ST.
    • Target Oncol. 2018 Aug;13(4):533-539. doi: 10.1007/s11523-018-0582-1.
    • Review
    • Using PARP Inhibitors in Advanced Ovarian Cancer.
    • O'Cearbhaill RE.
    • Oncology (Williston Park). 2018 Jul 15;32(7). pii: 614793.
    • BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    • Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    • Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.
    • An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    • Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer HN, Lyons JF, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.
    • Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.
    • Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
    • Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.
    • Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.
    • Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.
    • Dal Molin GZ, Omatsu K, Sood AK, Coleman RL.
    • Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483. doi: 10.1177/1758835918778483. eCollection 2018.
    • Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series.
    • Matsuo K, Spragg SE, Ciccone MA, Blake EA, Ricker C, Pham HQ, Roman LD.
    • Gynecol Oncol Rep. 2018 Jun 20;25:98-101. doi: 10.1016/j.gore.2018.06.011. eCollection 2018 Aug.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di L
    • Clin Cancer Res. 2018 Jun 12. doi: 10.1158/1078-0432.CCR-17-3862. [Epub ahead of print]
    • Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    • Mirza MR, Pignata S, Ledermann JA.
    • Ann Oncol. 2018 Jun 1;29(6):1366-1376. doi: 10.1093/annonc/mdy174.
    • Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
    • Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.
    • Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.
    • Management of newly diagnosed or recurrent ovarian cancer.
    • Matulonis UA.
    • Clin Adv Hematol Oncol. 2018 Jun;16(6):426-437.
    • Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
    • Moore KN, Birrer MJ.
    • Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28.
    • Review
    • Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
    • Dai Y, Sun C, Feng Y, Jia Q, Zhu B.
    • J Cell Mol Med. 2018 May 31. doi: 10.1111/jcmm.13678. [Epub ahead of print]
    • Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    • Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F.
    • Drug Des Devel Ther. 2018 May 29;12:1501-1509. doi: 10.2147/DDDT.S124447. eCollection 2018.
    • Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.
    • Arora E, Masab M, Jindal V, Riaz I, Gupta S, Varadi G.
    • Cureus. 2018 May 24;10(5):e2685. doi: 10.7759/cureus.2685.
    • Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
    • Fan FS, Yang CF.
    • J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
    • Delgado-Ortega L, Ginés Rubió J, Garcías de España MDC, Carcedo D, Cordero Puentes L, Moya de Alarcón C.
    • Farm Hosp. 2018 May 1;42(3):95-102. doi: 10.7399/fh.10904.
    • Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    • Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P.
    • Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23.
    • Review
    • Rucaparib: a new treatment option for ovarian cancer.
    • Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Lorusso D.
    • Expert Opin Pharmacother. 2018 May;19(7):765-771. doi: 10.1080/14656566.2018.1464557. Epub 2018 Apr 19.
    • Review
    • New Therapies for Ovarian Cancer.
    • Armstrong DK.
    • J Natl Compr Canc Netw. 2018 May;16(5S):632-635. doi: 10.6004/jnccn.2018.0034.
    • Review
    • Olaparib in Breast Cancer: PFS Is Significant but OS Is Not.
    • Castellino AM.
    • Medscape. Medscape Medical News. 2018 Apr 18.
    • Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus.
    • Capoluongo E, Scambia G, Nabholtz JM.
    • Oncotarget. 2018 Apr 13;9(28):19463-19468. doi: 10.18632/oncotarget.24728. eCollection 2018 Apr 13.
    • Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
    • Dasa SSK, Diakova G, Suzuki R, Mills AM, Gutknecht MF, Klibanov AL, Slack-Davis JK, Kelly KA.
    • Theranostics. 2018 Apr 11;8(10):2782-2798. doi: 10.7150/thno.23050. eCollection 2018.
    • Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
    • Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D.
    • Cell Rep. 2018 Apr 3;23(1):100-111. doi: 10.1016/j.celrep.2018.03.038.
    • PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
    • Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC.
    • Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20.
    • Crosstalk of DNA double-strand break repair pathways in PARP inhibitor treatment of BRCA1/2-mutated Cancer.
    • Sunada S, Nakanishi A, Miki Y.
    • Cancer Sci. 2018 Apr;109(4):893-899. doi: 10.1111/cas.13530. Epub 2018 Mar 6.
    • [Molecular Targeted Therapies for Hereditary Cancer Syndrome].
    • Shimodaira H.
    • Gan To Kagaku Ryoho. 2018 Apr;45(4):587-592.
    • Review, [Article in Japanese]
    • The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    • Moore KN, Mirza MR, Matulonis UA.
    • Gynecol Oncol. 2018 Apr;149(1):214-220. doi: 10.1016/j.ygyno.2018.01.011. Epub 2018 Feb 4.
    • Review
    • Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    • Fang L, Wang H, Li P.
    • Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.
    • Targeting DNA repair: the genome as a potential biomarker.
    • Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA.
    • J Pathol. 2018 Apr;244(5):586-597. doi: 10.1002/path.5025. Epub 2018 Feb 10.
    • Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature.
    • Herold N, Wappenschmidt B, Markiefka B, Keupp K, Kröber S, Hahnen E, Schmutzler R, Rhiem K.
    • Oncol Lett. 2018 Apr;15(4):4093-4096. doi: 10.3892/ol.2018.7836. Epub 2018 Jan 22.
    • Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    • Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.
    • BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.
    • Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.
    • Colombo I, Lheureux S, Oza AM.
    • Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018.
    • Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
    • Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.
    • The NCI-MATCH trial and precision medicine in gynecologic cancers.
    • Barroilhet L, Matulonis U.
    • Gynecol Oncol. 2018 Mar;148(3):585-590. doi: 10.1016/j.ygyno.2018.01.008. Epub 2018 Feb 1.
    • Review
    • Major clinical research advances in gynecologic cancer in 2017.
    • Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen MK, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2018 Mar;29(2):e31. doi: 10.3802/jgo.2018.29.e31.
    • Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
    • Jerzak KJ, Deghan Manshadi S, Ng P, Maganti M, McCuaig JM, Bulter M, Oza A, Mackay HJ.
    • J Oncol Pharm Pract. 2018 Mar;24(2):83-90. doi: 10.1177/1078155216679028. Epub 2016 Nov 17.
    • Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    • Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes FJ, Mannel RS, Glaser G, Bailey C, Rubin SC, Soper JT, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.
    • Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.
    • Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.
    • Mylavarapu S, Das A, Roy M.
    • Front Oncol. 2018 Feb 5;8:16. doi: 10.3389/fonc.2018.00016. eCollection 2018.
    • Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
    • Eetezadi S, Evans JC, Shen YT, De Souza R, Piquette-Miller M, Allen C.
    • Mol Pharm. 2018 Feb 5;15(2):472-485. doi: 10.1021/acs.molpharmaceut.7b00843. Epub 2018 Jan 22.
    • Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
    • Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W.
    • Cancer Chemother Pharmacol. 2018 Feb;81(2):255-267. doi: 10.1007/s00280-017-3483-6. Epub 2017 Nov 30.
    • Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    • McCann KE.
    • Curr Opin Obstet Gynecol. 2018 Feb;30(1):7-16. doi: 10.1097/GCO.0000000000000428.
    • Review
    • The development of PARP as a successful target for cancer therapy.
    • Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.
    • Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26.
    • Review
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.
    • Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM.
    • J Genet Couns. 2018 Feb;27(1):131-139. doi: 10.1007/s10897-017-0130-7. Epub 2017 Aug 5.
    • PARP Inhibitors for the Treatment of Ovarian Cancer.
    • Cortesi L, Toss A, Cucinotto I.
    • Curr Cancer Drug Targets. 2018;18(9):877-893. doi: 10.2174/1568009618666180308104646.
    • Review
    • PARP Inhibitors in Ovarian Cancer.
    • Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G.
    • Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256.
    • Review
    • Gene aberration profile of tumors of adolescent and young adult females.
    • Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.
    • Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.
    • Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    • Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP.
    • Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620-7. doi: 10.1016/j.ygyno.2017.12.029. [Epub ahead of print]
    • Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
    • Hollis RL, Meynert AM, Churchman M, Rye T, Mackean M, Nussey F, Arends MJ, Sims AH, Semple CA, Herrington CS, Gourley C.
    • BMC Cancer. 2018 Jan 3;18(1):16. doi: 10.1186/s12885-017-3981-2.
    • Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
    • Markman M.
    • Womens Health (Lond). 2018 Jan-Dec;14:1745505717750694. doi: 10.1177/1745505717750694.
    • Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    • Wan B, Dai L, Wang L, Zhang Y, Huang H, Qian G, Yu T.
    • Endocr Relat Cancer. 2018 Jan;25(1):69-82. doi: 10.1530/ERC-17-0261. Epub 2017 Oct 24.
    • BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
    • Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T.
    • Int J Gynecol Cancer. 2018 Jan;28(1):69-76. doi: 10.1097/IGC.0000000000001144.
    • Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
    • Jin M, Cai J, Wang X, Zhang T, Zhao Y.
    • Cancer Biol Ther. 2018;19(12):1088-1092. doi: 10.1080/15384047.2018.1491500. Epub 2018 Aug 15.
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • PARP Inhibitors in Epithelial Ovarian Cancer.
    • Taylor KN, Eskander RN.
    • Recent Pat Anticancer Drug Discov. 2018;13(2):145-158. doi: 10.2174/1574892813666171204094822.
    • Olaparib.
    • Bochum S, Berger S, Martens UM.
    • Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.
    • Review
    • Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
    • Berchuck A, Secord AA, Moss HA, Havrilesky LJ.
    • J Clin Oncol. 2017 Dec 20;35(36):3999-4002. doi: 10.1200/JCO.2017.74.5752. Epub 2017 Oct 26.
    • BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    • Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.
    • Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.
    • Emerging treatment options for ovarian cancer: focus on rucaparib.
    • Mariappan L, Jiang XY, Jackson J, Drew Y.
    • Int J Womens Health. 2017 Dec 15;9:913-924. doi: 10.2147/IJWH.S151194. eCollection 2017.
    • Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.
    • Audibert C, Perlaky A, Stuntz M, Glass D.
    • Drug Des Devel Ther. 2017 Dec 6;11:3471-3479. doi: 10.2147/DDDT.S151420. eCollection 2017.
    • The OlympiAD trial: who won the gold?
    • Gyawali B.
    • Ecancermedicalscience. 2017 Dec 6;11:ed75. doi: 10.3332/ecancer.2017.ed75. eCollection 2017.
    • FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.
    • Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, Song P, Pierce W, Robertson KJ, Palmby TR, Chiu HJ, Lee EY, Philip R, Schuck R, Charlab R, Banerjee A, Chen XH, Wang X, Goldberg KB, Sridhara R, Kim G, Pazdur R.
    • Clin Cancer Res. 2017 Dec 1;23(23):7165-7170. doi: 10.1158/1078-0432.CCR-17-1337. Epub 2017 Jul 27.
    • Summary
    • Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2-ovarian cancers.
    • Bueno R, Mar JC.
    • Methods. 2017 Dec 1;131:74-82. doi: 10.1016/j.ymeth.2017.07.021. Epub 2017 Jul 25.
    • Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
    • Dockery LE, Tew WP, Ding K, Moore KN.
    • Gynecol Oncol. 2017 Dec;147(3):509-513. doi: 10.1016/j.ygyno.2017.10.007. Epub 2017 Oct 14.
    • PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    • Bitler BG, Watson ZL, Wheeler LJ, Behbakht K.
    • Gynecol Oncol. 2017 Dec;147(3):695-704. doi: 10.1016/j.ygyno.2017.10.003. Epub 2017 Oct 14.
    • PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
    • Sisay M, Edessa D.
    • Gynecol Oncol Res Pract. 2017 Nov 29;4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017.
    • High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.
    • Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.
    • Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.
    • Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.
    • Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.
    • Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.
    • Deniz M, Romashova T, Kostezka S, Faul A, Gundelach T, Moreno-Villanueva M, Janni W, Friedl TWP, Wiesmüller L.
    • Oncotarget. 2017 Oct 9;8(58):98660-98676. doi: 10.18632/oncotarget.21720. eCollection 2017 Nov 17.
    • Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
    • Wang Y, Ung MH, Cantor S, Cheng C.
    • Sci Rep. 2017 Nov 16;7(1):15742. doi: 10.1038/s41598-017-16138-2.
    • Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
    • Garber J.
    • OncoTherapy Network. 2017 Nov 15.
    • BRCA mutations in the manifestation and treatment of ovarian cancer.
    • Pan Z, Xie X.
    • Oncotarget. 2017 May 30;8(57):97657-97670. doi: 10.18632/oncotarget.18280. eCollection 2017 Nov 14.
    • Checkpoint and PARP inhibitors, for whom and when.
    • Lee JM, Gulley JL.
    • Oncotarget. 2017 Sep 12;8(56):95036-95037. doi: 10.18632/oncotarget.20852. eCollection 2017 Nov 10.
    • 'Important' Progress in Gynecologic Cancers: ESMO 2017.
    • Susana Banerjee
    • Medscape. News & Perspective. 2017 Nov 3.
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441.
    • Review, Conference abstract
    • Differential toxicity in patients with and without DNA repair mutations: Phase I Study of Carboplatin and Talazoparib in advanced solid tumors.
    • Dhawan MS, Bartelink IH, Aggarwal R, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser MM, Kelley RK, Maktabi T, Thomas S, Munster PN.
    • Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8.
    • Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    • Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, Garcia-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J1, Reis-Filho JS, Greenberg RA, Robson M, Turner NC.
    • Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.
    • Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    • Gadducci A, Guerrieri ME.
    • Anticancer Res. 2017 Nov;37(11):5955-5965.
    • Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
    • Kawahara N, Ogawa K, Nagayasu M, Kimura M, Sasaki Y, Kobayashi H.
    • Biomed Rep. 2017 Nov;7(5):391-399. doi: 10.3892/br.2017.990. Epub 2017 Sep 27.
    • [Abnormalities of DNA repair and gynecological cancers].
    • Auguste A, Leary A.
    • Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18.
    • Review, [Article in French]
    • [DNA repair as a therapeutic target].
    • Eberst L, Brahmi M, Cassier PA.
    • Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11.
    • Review, [Article in French]
    • Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    • Hoskins PJ, Gotlieb WH.
    • CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.
    • Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
    • Trafalis DT, Polonifi A, Dalezis P, Nikoleousakos N, Katsamakas S, Sarli V.
    • Chem Biol Drug Des. 2017 Nov;90(5):854-866. doi: 10.1111/cbdd.13006. Epub 2017 May 26.
    • Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    • Vanderstichele A, Busschaert P, Olbrecht S, Lambrechts D, Vergote I.
    • Eur J Cancer. 2017 Nov;86:5-14. doi: 10.1016/j.ejca.2017.08.029. Epub 2017 Sep 23.
    • Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    • Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.
    • Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.
    • Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
    • Steffensen KD, Adimi P, Jakobsen A.
    • Int J Gynecol Cancer. 2017 Nov;27(9):1842-1849. doi: 10.1097/IGC.0000000000001089.
    • Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    • Johnson N, Liao JB.
    • Int J Gynecol Cancer. 2017 Nov;27(9S Suppl 5):S14-S19. doi: 10.1097/IGC.0000000000001115.
    • Conference report
    • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators.
    • Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.

    Comment:

    PARP inhibitors for targeted treatment in ovarian cancer.

    • Mitigating Side Effects to Reach PARP Inhibitors' Potential.
    • Markman M.
    • Medscape. News & Perspective. 2017 Oct 13.
    • Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
    • Thomas SN, Chen L, Liu Y, Hoti N, Zhang H.
    • J Proteome Res. 2017 Oct 6;16(10):3704-3710. doi: 10.1021/acs.jproteome.7b00405. Epub 2017 Sep 14.
    • The HRD decision--which PARP inhibitor to use for whom and when.
    • Kohn EC, Lee JM, Ivy SP.
    • Clin Cancer Res. 2017 Oct 3. doi: 10.1158/1078-0432.CCR-17-2186. [Epub ahead of print]
    • Revew
    • Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.
    • González-Martín A.
    • Future Oncol. 2017 Oct;13(23s):3-9. doi: 10.2217/fon-2017-0316. Epub 2017 Oct 11.
    • Review, Conference report
    • Trabectedin mechanism of action and platinum resistance: molecular rationale.
    • Ray-Coquard I.
    • Future Oncol. 2017 Oct;13(23s):17-21. doi: 10.2217/fon-2017-0318. Epub 2017 Oct 11.
    • Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
    • van Haaften C, van Eendenburg J, Boot A, Corver WE, Haans L, van Wezel T, Trimbos JB.
    • Int J Gynecol Cancer. 2017 Oct;27(8):1571-1578. doi: 10.1097/IGC.0000000000001052.
    • BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
    • Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.
    • Tumour Biol. 2017 Oct;39(10):1010428317727479. doi: 10.1177/1010428317727479.
    • The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
    • Strumidło A, Skiba S, Scott RJ, Lubiński J.
    • Hered Cancer Clin Pract. 2017 Sep 29;15:15. doi: 10.1186/s13053-017-0076-7. eCollection 2017.
    • Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.
    • Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L.
    • Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10.
    • Checkpoint and PARP inhibitors, for whom and when.
    • Lee JM, Gulley JL.
    • Oncotarget. 2017 Sep 12. doi: 10.18632/oncotarget.20852. [Epub ahead of print]
    • Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
    • Herzog TJ, Monk BJ.
    • Gynecol Oncol Res Pract. 2017 Sep 7;4:13. doi: 10.1186/s40661-017-0050-0. eCollection 2017.
    • BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    • Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    • Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
    • Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma.
    • Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K, Scott CL.
    • Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    • Chung C, Lee R.
    • J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29.
    • Review
    • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    • Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.
    • Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.

    Research report, Comment:

    To promote maintenance or treatment, is that the question?

    Press: Olaparib Prolongs Progression-Free Survival in Relapsed Ovarian Cancer. (Medscape/Reuters)

    • Niraparib in ovarian cancer: results to date and clinical potential.
    • Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F.
    • Ther Adv Med Oncol. 2017 Sep;9(9):579-588. doi: 10.1177/1758834017718775. Epub 2017 Jul 12.
    • FDA Approves New Indication and Formulation for Olaparib.
    • Nelson R.
    • Medscape. 2017 Aug 17.
    • Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.
    • Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, Foulkes WD.
    • Cancer Res. 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.
    • Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
    • Yuan Z, Chen S, Sun Q, Wang N, Li D, Miao S, Gao C, Chen Y, Tan C, Jiang Y.
    • Bioorg Med Chem. 2017 Aug 1;25(15):4100-4109. doi: 10.1016/j.bmc.2017.05.058. Epub 2017 May 31.
    • Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    • Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson D, Timms KM, Lanchbury JS, Kaye SB, Gourley C, Bowtell DD, Kohn EC, Scott CL, Matulonis UA, Panzarella T, Karakasis K, Burnier JV, Gilks B, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.
    • Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.
    • A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
    • Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso PM, Patel M, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.
    • Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.
    • Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
    • Do TV, Hirst J, Hyter S, Roby KF, Godwin AK.
    • Oncotarget. 2017 Jul 5;8(31):50376-50392. doi: 10.18632/oncotarget.18970. eCollection 2017 Aug 1.
    • A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    • Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH.
    • Gynecol Oncol. 2017 Aug;146(2):399-404. doi: 10.1016/j.ygyno.2017.05.037. Epub 2017 Jun 10.
    • Malignant Brenner tumor associated with a germline BRCA2 mutation.
    • Toboni MD, Smith HJ, Dilley SE, Novak L, Leath CA.
    • Gynecol Oncol Rep. 2017 May 31;21:17-19. doi: 10.1016/j.gore.2017.05.006. eCollection 2017 Aug.
    • Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
    • Oda K, Tanikawa M, Sone K, Mori-Uchino M, Osuga Y, Fujii T.
    • Int J Clin Oncol. 2017 Aug;22(4):611-618. doi: 10.1007/s10147-017-1137-7. Epub 2017 May 15.
    • Review
    • Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    • Murai J.
    • Int J Clin Oncol. 2017 Aug;22(4):619-628. doi: 10.1007/s10147-017-1145-7. Epub 2017 Jun 22.
    • Review
    • BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
    • Neff RT, Senter L, Salani R.
    • Ther Adv Med Oncol. 2017 Aug;9(8):519-531. doi: 10.1177/1758834017714993. Epub 2017 Jun 19.
    • Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma.
    • Conroy M, Borad MJ, Bryce AH.
    • Cureus. 2017 Jul 26;9(7):e1517. doi: 10.7759/cureus.1517.
    • Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
    • Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.
    • Sci Transl Med. 2017 Jul 26;9(400). pii: eaal1645. doi: 10.1126/scitranslmed.aal1645.
    • Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    • Rafii S, Gourley C, Kumar R, Geuna E, Ang JE, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    • Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.
    • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    • Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.
    • Oncotarget. 2017 Jul 4;8(27):43653-43661. doi: 10.18632/oncotarget.17613.

    Research news:

    Olaparib and somatic BRCA mutations.

    • Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    • Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV, Preobrazhenskaya EV, Kleshchov MA, Tyurin VI, Mukhina MS, Kotiv KB, Shulga AV, Kuznetsov SG, Berlev IV, Imyanitov EN.
    • Cancer Lett. 2017 Jul 1;397:127-132. doi: 10.1016/j.canlet.2017.03.036. Epub 2017 Apr 1.
    • Development of PARP inhibitors in gynecological malignancies.
    • Ang YLE, Tan DSP.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14.
    • Review
    • Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
    • Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.
    • Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
    • Graybill WS, Pothuri B, Chase DM, Monk BJ.
    • Gynecol Oncol. 2017 Jul;146(1):11-15. doi: 10.1016/j.ygyno.2017.03.508. Epub 2017 Apr 6.
    • Editorial, Commentary
    • Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    • Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW.
    • Gynecol Oncol. 2017 Jul;146(1):58-63. doi: 10.1016/j.ygyno.2017.04.011. Epub 2017 Apr 26.
    • Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    • Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group.
    • J Gynecol Oncol. 2017 Jul;28(4):e39. doi: 10.3802/jgo.2017.28.e39.
    • Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    • Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.
    • J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.
    • Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.
    • Dockery LE, Gunderson CC, Moore KN.
    • Onco Targets Ther. 2017 Jun 19;10:3029-3037. doi: 10.2147/OTT.S114714. eCollection 2017.
    • Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
    • Meyer S, Stevens A, Paredes R, Schneider M, Walker MJ, Williamson AJK, Gonzalez-Sanchez MB, Smetsers S, Dalal V, Teng HY, White DJ, Taylor S, Muter J, Pierce A, de Leonibus C, Rockx DAP, Rooimans MA, Spooncer E, Stauffer S, Biswas K, Godthelp B, Dorsman J, Clayton PE, Sharan SK, Whetton AD.
    • Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.
    • Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    • Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F.
    • Clin Cancer Res. 2017 Jun 15;23(12):3097-3108. doi: 10.1158/1078-0432.CCR-16-2273. Epub 2016 Dec 19.
    • OlympiAD: Olaparib Captures Gold for BRCA-Mutated Breast Cancer Patients.
    • Miller KD, Domchek SM.
    • Medscape. Coverage from the ASCO 2017 Annual Meeting. 2017 Jun 12.
    • Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
    • Cuyàs E, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    • Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. [Presented Friday, June 2, 2017.] 2017;37:443-448. doi: 10.14694/EDBK_174718.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
    • Gadducci A, Guerrieri ME.
    • Crit Rev Oncol Hematol. 2017 Jun;114:153-165. doi: 10.1016/j.critrevonc.2017.04.006. Epub 2017 Apr 20.

    Commentary: 'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer. (Medscape Oncology)

    • Niraparib: First Global Approval.
    • Scott LJ.
    • Drugs. 2017 Jun;77(9):1029-1034. doi: 10.1007/s40265-017-0752-y.
    • Review
    • Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    • Talens F, Jalving M, Gietema JA, van Vugt MATM.
    • Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2.
    • The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
    • Lorusso D, Fontanella C, Maltese G, Lepori S, Tripodi E, Bogani G, Raspagliesi F.
    • Expert Opin Drug Saf. 2017 Jun;16(6):687-696. doi: 10.1080/14740338.2017.1325871. Epub 2017 May 18.
    • Review
    • [Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.] [The role of niraparib in the treatment of ovarian cancer: actuality and perspectives]
    • Sabatucci I, Lorusso D.
    • Recenti Prog Med. 2017 Jun;108(6):265-268. doi: 10.1701/2715.27713.
    • Review, [Article in Italian]
    • [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.]
    • Angius G, Sepe P, Papa A, Tomao S, Tomao F.
    • Recenti Prog Med. 2017 Jun;108(6):269-281. doi: 10.1701/2715.27714.
    • Review, [Article in Italian]
    • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    • Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG.
    • Semin Oncol. 2017 Jun;44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. Epub 2017 Sep 15.
    • Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
    • Di Napoli M, Della Pepa C, Arenare L, Scambia G, Lorusso D, Raspagliesi F, Ferrandina G, Salutari V, Sorio R, Mosconi AM, Mangili G, Borgato L, Lepori S, Salvino A, Pignata S, Cecere SC.
    • Support Care Cancer. 2017 Jun;25(6):1743-1748. doi: 10.1007/s00520-016-3547-x. Epub 2017 Jan 19.
    • Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
    • Hollis RL, Churchman M, Gourley C.
    • Onco Targets Ther. 2017 May 11;10:2539-2551. doi: 10.2147/OTT.S102569. eCollection 2017.
    • Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.
    • Rubio Pérez MJ.
    • Case Rep Oncol. 2017 May 9;10(2):433-437. doi: 10.1159/000475707. eCollection 2017 May-Aug.
    • A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    • Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.
    • Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):443-448. doi: 10.1200/EDBK_174718.
    • Cancers de l’ovaire BRCA muté : consultation d’oncogénétique et prescription des inhibiteurs de PARP. [BRCA-mutated Ovarian Carcinomas: Genetic Counseling and PARP Inhibitors Prescription.]
    • Gladieff L, Lyonnet DS, Lortholary A, Leary A, Genestie C, Ray-Coquard I.
    • Bull Cancer. 2017 May;104 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(17)30158-3.
    • Review, [Article in French]
    • Traitement des rechutes tardives du cancer de l’ovaire. [Treatment for Platinum-Sensitive Relapses of Ovarian Cancer.]
    • Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard AC, You B.
    • Bull Cancer. 2017 May;104 Suppl 1:S24-S31. doi: 10.1016/S0007-4551(17)30159-5.
    • Review, [Article in French]
    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
    • George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.
    • Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.
    • Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    • Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay ME, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.
    • Int J Gynecol Cancer. 2017 May;27(4):708-713. doi: 10.1097/IGC.0000000000000945.
    • Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
    • George A, Kaye S, Banerjee S.
    • Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13.
    • Review
    • Myriad to Use BRACAnalysis CDx as Companion Diagnostic for Clovis' Ovarian Cancer Treatment.
    • [No author given]
    • Clinical Omics. 2017 Apr 27.
    • Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    • Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL.
    • J Clin Oncol. 2017 Apr 20;35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. Epub 2017 Feb 13.
    • Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    • McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ.
    • Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4.
    • Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
    • Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B.
    • Elife. 2017 Apr 11;6. pii: e21350. doi: 10.7554/eLife.21350.
    • Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    • Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.
    • J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.
    • PARP Inhibitors for Cancer Therapy.
    • Lin KY, Kraus WL.
    • Cell. 2017 Apr 6;169(2):183. doi: 10.1016/j.cell.2017.03.034.
    • Review
    • Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
    • El Bairi K, Kandhro AH, Gouri A, Mahfoud W, Louanjli N, Saadani B, Afqir S, Amrani M.
    • Cell Oncol (Dordr). 2017 Apr;40(2):105-118. doi: 10.1007/s13402-016-0309-1. Epub 2016 Dec 15.
    • Review
    • Rucaparib: First Global Approval.
    • Syed YY.
    • Drugs. 2017 Apr;77(5):585-592. doi: 10.1007/s40265-017-0716-2.
    • Review
    • Niraparib for the treatment of ovarian cancer.
    • Kanjanapan Y, Lheureux S, Oza AM.
    • Expert Opin Pharmacother. 2017 Apr;18(6):631-640. doi: 10.1080/14656566.2017.1297423. Epub 2017 Apr 7.
    • Review
    • Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    • Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.
    • J Immunother. 2017 Apr;40(3):104-107. doi: 10.1097/CJI.0000000000000160.
    • Case report
    • PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
    • Evans T, Matulonis U.
    • Ther Adv Med Oncol. 2017 Apr;9(4):253-267. doi: 10.1177/1758834016687254. Epub 2017 Feb 3.
    • Niraparib for the treatment of ovarian cancer.
    • Kanjanapan Y, Lheureux S, Oza AM.
    • Expert Opin Pharmacother. 2017 Mar 16. doi: 10.1080/14656566.2017.1297423. [Epub ahead of print]
    • Review
    • Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.
    • Olaparib Maintenance Therapy Boosts PFS in Ovarian Cancer.
    • Nelson R.
    • Medscape. 2017 Mar 14.
    • Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.
    • McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY.
    • NPJ Syst Biol Appl. 2017 Mar 6;3:8. doi: 10.1038/s41540-017-0011-6. eCollection 2017.
    • Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    • Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.
    • Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.
    • Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.
    • Kurian AW, Friese CR, Bondarenko I, Jagsi R, Li Y, Hamilton AS, Ward KC, Katz SJ.
    • JAMA Oncol. 2017 Mar 1;3(3):391-397. doi: 10.1001/jamaoncol.2016.5652.
    • Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    • Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.
    • Cancer Chemother Pharmacol. 2017 Mar;79(3):587-594. doi: 10.1007/s00280-017-3262-4. Epub 2017 Feb 28.
    • A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
    • Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS.
    • Gynecol Oncol. 2017 Mar;144(3):486-490. doi: 10.1016/j.ygyno.2017.01.016. Epub 2017 Jan 18.
    • HDAC10 as a potential therapeutic target in ovarian cancer.
    • Islam MM, Banerjee T, Packard CZ, Kotian S, Selvendiran K, Cohn DE, Parvin JD.
    • Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.
    • [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
    • Löser H, Heydt C, Büttner R, Markiefka B.
    • Pathologe. 2017 Mar;38(2):117-126. doi: 10.1007/s00292-017-0274-0.
    • Review, [Article in German]
    • Pharmaceutical Approval Update.
    • Choy M.
    • P T. 2017 Mar;42(3):165-166.
    • Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    • Frey MK, Pothuri B.
    • Gynecol Oncol Res Pract. 2017 Feb 22;4:4. doi: 10.1186/s40661-017-0039-8. eCollection 2017.
    • Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
    • De Jaeghere E, Vandecasteele K, Claes K, Makar A, Tummers P, Cocquyt V, Denys H.
    • Acta Clin Belg. 2017 Feb;72(1):6-11. doi: 10.1080/17843286.2016.1188455. Epub 2016 May 31.
    • Review
    • PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.
    • Sander Effron S, Makvandi M, Lin L, Xu K, Li S, Lee H, Hou C, Pryma DA, Koch C, Mach RH.
    • Cancer Biother Radiopharm. 2017 Feb;32(1):9-15. doi: 10.1089/cbr.2016.2133. Epub 2017 Jan 24.
    • Rucaparib Approved for Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2017 Feb;7(2):120-121. doi: 10.1158/2159-8290.CD-NB2016-164. Epub 2017 Jan 5.
    • News
    • Integrating genomic information and signaling dynamics for efficient cancer therapy.
    • Stewart-Ornstein J, Lahav G.
    • Curr Opin Syst Biol. 2017 Feb;1:38-43. doi: 10.1016/j.coisb.2016.12.013. Epub 2016 Dec 19.
    • Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    • Rzepecka IK, Szafron LM, Stys A, Felisiak-Golabek A, Podgorska A, Timorek A, Sobiczewski P, Pienkowska-Grela B, El-Bahrawy M, Kupryjanczyk J.
    • Gynecol Oncol. 2017 Feb;144(2):369-376. doi: 10.1016/j.ygyno.2016.11.028. Epub 2016 Dec 7.
    • Novel BRCA1 and BRCA2 Tumour Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    • Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, van Asseldonk M, Gomez-Garcia EB, Blok MJ, de Hullu JA, Nelen MR, Hoischen A, Bulten J, Tops BB, Hoogerbrugge N, Ligtenberg EM.
    • Hum Mutat. 2017 Feb;38(2):226-235. doi: 10.1002/humu.23137. Epub 2016 Nov 9.
    • [Can new molecular profiles in epithelial ovarian cancer modify therapeutics?]
    • Lavoué V, Rousselin A, Delplanque S, Pinsard M, Henno S, Foucher F, Levêque J, de la Motte Rouge T.
    • J Gynecol Obstet Hum Reprod. 2017 Feb;46(2):107-112. doi: 10.1016/j.jogoh.2016.09.002. Epub 2017 Jan 30.
    • Review, [Article in French]
    • Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
    • Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.
    • Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.
    • The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.
    • Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E.
    • Int J Mol Sci. 2017 Jan 20;18(1). pii: E210. doi: 10.3390/ijms18010210.
    • Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    • Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ.
    • BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.
    • Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
    • Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL.
    • JAMA Oncol. 2017 Jan 1;3(1):76-82. doi: 10.1001/jamaoncol.2016.4411.
    • Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2017 Jan;7(1):OF8. doi: 10.1158/2159-8290.CD-RW2016-230. Epub 2016 Dec 9.
    • Research News
    • Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
    • Lambertini M, Del Mastro L, Viglietti G, Pondé NF, Solinas C, de Azambuja E.
    • Curr Treat Options Oncol. 2017 Jan;18(1):4. doi: 10.1007/s11864-017-0442-8.
    • Review
    • Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    • Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, Facchini G, Gargiulo P, Rossetti S, Mangili G, Pignata S, Cecere SC.
    • Gynecol Oncol. 2017 Jan;144(1):72-76. doi: 10.1016/j.ygyno.2016.10.023. Epub 2016 Oct 27.
    • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    • Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.
    • Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

    Comment:

    Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?

    • Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    • Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S, Tidy J.
    • Pharmacoeconomics. 2017 Jan;35(1):97-109. doi: 10.1007/s40273-016-0440-x.
    • Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.
    • [No authors listed]
    • Prescrire Int. 2017 Jan;26(178):9-12.
    • Fork Protection and Therapy Resistance in Hereditary Breast Cancer.
    • Cantor SB, Calvo JA.
    • Cold Spring Harb Symp Quant Biol. 2017;82:339-348. doi: 10.1101/sqb.2017.82.034413. Epub 2018 Feb 22.
    • Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor Olaparib by a dominant negative effect.
    • Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro AN, Benítez J, Osorio A.
    • Hum Mol Genet. 2016 Dec 15;25(24):5287-5299. doi: 10.1093/hmg/ddw343.
    • Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
    • Friedlander M, Banerjee S, Mileshkin L, Scott C, Shannon C, Goh J.
    • Asia Pac J Clin Oncol. 2016 Dec;12(4):323-331. doi: 10.1111/ajco.12636.
    • Niraparib Slows Ovarian Cancer Progression.
    • [No authors listed]
    • Cancer Discov. 2016 Dec;6(12):OF2. Epub 2016 Nov 3.
    • News
    • Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    • Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.
    • Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4.
    • Review
    • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
    • Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.
    • N Engl J Med. 2016 Dec;375(22):2154-2164. Epub 2016 Oct 7.

    Editorial, Comment:

    PARP Inhibitors in Ovarian Cancer Treatment.

    Letter, Comment:

    Niraparib in Recurrent Ovarian Cancer.

    Press: New PARP Drug 'Could Benefit Most Ovarian Cancer Patients'. (Medscape)

    • PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.
    • Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A.
    • Prz Menopauzalny. 2016 Dec;15(4):215-219. doi: 10.5114/pm.2016.65667. Epub 2017 Feb 8.
    • Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
    • Egloff H, Jatoi A.
    • Cancer Invest. 2016 Nov 25;34(10):531-535. Epub 2016 Oct 28.
    • Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U.
    • Br J Cancer. 2016 Nov 22;115(11):1313-1320. doi: 10.1038/bjc.2016.348. Epub 2016 Nov 8.
    • PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    • Konecny GE, Kristeleit RS.
    • Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13.
    • Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    • Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.
    • Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15.
    • Review
    • [Perspectives of Individualized Treatment by Genome-Wide Analyses in Ovarian Cancer].
    • Matsumura N, Yamaguchi K, Murakami R, Mandai M, Konishi I.
    • Gan To Kagaku Ryoho. 2016 Nov;43(11):1316-1320.
    • [Article in Japanese]
    • In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    • AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.
    • Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.
    • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    • Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
    • Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.
    • Bangham M, Goldstein R, Walton H, Ledermann JA.
    • Gynecol Oncol Rep. 2016 Oct 19;18:22-24. eCollection 2016.
    • The current status of PARP inhibitors in ovarian cancer.
    • McLachlan J, George A, Banerjee S.
    • Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
    • Review
    • The race to create a new class of ovarian cancer drugs heats up.
    • Meghana Keshavan
    • STAT. 2016 Oct 8.
    • Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
    • Sabatier R, Lavit E, Moretta J, Lambaudie E, Noguchi T, Eisinger F, Cherau E, Provansal M, Livon D, Rabayrol L, Popovici C, Charaffe-Jauffret E, Sobol H, Viens P.
    • Fam Cancer. 2016 Oct;15(4):497-506. doi: 10.1007/s10689-016-9873-9.
    • Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    • Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D.
    • Gynecol Oncol. 2016 Oct;143(1):143-51. doi: 10.1016/j.ygyno.2016.07.088. Epub 2016 Jul 19.
    • Ovarian cancer treatment in mutation carriers/brcaness.
    • Lorusso D, Perotto S.
    • Minerva Ginecol. 2016 Oct;68(5):566-78. Epub 2016 Jan 19.
    • Review
    • Linking genotoxicity and cytotoxicity with membrane fluidity: A comparative study in ovarian cancer cell lines following exposure to auranofin.
    • Oommen D, Dodd NJ, Yiannakis D, Moyeed R, Jha AN.
    • Mutat Res. 2016 Oct;809:43-49. doi: 10.1016/j.mrgentox.2016.09.003. Epub 2016 Sep 4.
    • Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women's cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2016 Sep 23. pii: clincanres.1546.2016. [Epub ahead of print]
    • Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    • Papa A, Caruso D, Strudel M, Tomao S, Tomao F.
    • J Transl Med. 2016 Sep 15;14:267. doi: 10.1186/s12967-016-1027-1.
    • [BRCA1 and BRCA2 - pathologists starting kit].
    • Škapa P.
    • Cesk Patol. 2016 Fall;52(4):193-196.
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    • Vošmiková H, Ryška A, Sieglová K, Laco J.
    • Cesk Patol. 2016 Fall;52(4):210-214.
    • PTIP Loss Protects BRCA-Deficient Cells from DNA Damage and Cell Death.
    • [No authors listed]
    • Cancer Discov. 2016 Sep;6(9):944. doi: 10.1158/2159-8290.CD-RW2016-142. Epub 2016 Jul 29.
    • Research Watch
    • New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.
    • Vergote I, Bours V, Blaumeiser B, Baurain JF.
    • Facts Views Vis Obgyn. 2016 Sep;8(3):161-167.
    • Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.
    • Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, Gori S, Guarneri V, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, Tassone P, Truini M, Varesco L.
    • Future Oncol. 2016 Sep;12(18):2071-5. doi: 10.2217/fon-2016-0189. Epub 2016 May 31.
    • Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    • Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.
    • Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.
    • PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    • Crafton SM, Bixel K, Hays JL.
    • Gynecol Oncol. 2016 Sep;142(3):588-96. doi: 10.1016/j.ygyno.2016.05.003. Epub 2016 Jul 25.
    • Review
    • PARP Inhibitors Promising as Maintenance After Ovarian Cancer Remission.
    • Maurie Markman
    • Medscape Oncology. 2016 Aug 23.
    • All women with ovarian cancer should be offered genetic testing – so why aren’t they?
    • Emma Smith
    • Science Blog. Cancer Research UK. 2016 Aug 17.
    • BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    • Moschetta M, George A, Kaye SB, Banerjee S.
    • Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31.
    • Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    • Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    • Gynecol Oncol. 2016 Aug;142(2):323-31. doi: 10.1016/j.ygyno.2016.06.005. Epub 2016 Jun 16.
    • Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    • Moore KN, Monk BJ.
    • Oncologist. 2016 Aug;21(8):954-63. doi: 10.1634/theoncologist.2015-0268. Epub 2016 Jun 2.
    • MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    • Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES.
    • BMC Cancer. 2016 Jul 27;16(1):550. doi: 10.1186/s12885-016-2598-1.
    • Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients.
    • Zimmermann MT, Jiang G, Wang C.
    • AMIA Jt Summits Transl Sci Proc. 2016 Jul 20;2016:94-100. eCollection 2016.
    • Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
    • Munroe M, Kolesar J.
    • Am J Health Syst Pharm. 2016 Jul 15;73(14):1037-41. doi: 10.2146/ajhp150550.
    • Review
    • PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
    • Noll A, Illuzzi G, Amé JC, Dantzer F, Schreiber V.
    • Cancer Cell Int. 2016 Jul 1;16:53. doi: 10.1186/s12935-016-0333-2. eCollection 2016.
    • Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
    • Goyal G, Fan T, Silberstein PT.
    • Fam Cancer. 2016 Jul;15(3):359-66. doi: 10.1007/s10689-016-9883-7.
    • Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
    • Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA.
    • Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8.
    • Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    • Moore KN, Monk BJ.
    • Oncologist. 2016 Jun 2. pii: theoncologist.2015-0268. [Epub ahead of print]
    • Review
    • Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    • Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL.
    • Ann Oncol. 2016 Jun;27(6):1013-9. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8.
    • Homologous recombination deficiency and ovarian cancer.
    • Ledermann JA, Drew Y, Kristeleit RS.
    • Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9.
    • Review
    • The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    • Nirsimloo R, Gourley C.
    • Expert Rev Anticancer Ther. 2016 Jun;16(6):597-603. doi: 10.1080/14737140.2016.1182429.
    • Review
    • Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
    • Jenner ZB, Sood AK, Coleman RL.
    • Future Oncol. 2016 Jun;12(12):1439-56. doi: 10.2217/fon-2016-0002. Epub 2016 Apr 18.
    • Review
    • Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer.
    • Komiyama S, Katabuchi H, Mikami M, Nagase S, Okamoto A, Ito K, Morishige K, Suzuki N, Kaneuchi M, Yaegashi N, Udagawa Y, Yoshikawa H.
    • Int J Clin Oncol. 2016 Jun;21(3):435-46. doi: 10.1007/s10147-016-0985-x. Epub 2016 May 3.
    • Practice Guideline
    • Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.
    • Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z, Sun J.
    • Oncotarget. 2016 May 31;7(22):32433-48. doi: 10.18632/oncotarget.8653.
    • Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    • Kristeleit RS, Miller RE, Kohn EC.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):e259-e268. doi: 10.1200/EDBK_159086.
    • PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    • Gadducci A, Guerrieri ME.
    • Anticancer Res. 2016 May;36(5):2055-64.
    • Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    • De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI.
    • Crit Rev Oncol Hematol. 2016 May;101:50-9. doi: 10.1016/j.critrevonc.2016.02.014. Epub 2016 Feb 27.
    • Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
    • Ju LL, Zhao CY, Ye KF, Yang H, Zhang J.
    • Eur Rev Med Pharmacol Sci. 2016 May;20(10):1993-2003.
    • Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    • Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    • Expert Opin Investig Drugs. 2016 May;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16.
    • Olaparib for the treatment of epithelial ovarian cancer.
    • McLachlan J, Banerjee S.
    • Expert Opin Pharmacother. 2016 May;17(7):995-1003. doi: 10.1517/14656566.2016.1165205. Epub 2016 Apr 4.
    • Review
    • Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    • Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.
    • Gynecol Oncol. 2016 May;141(2):260-3. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11.
    • Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    • Parkes EE, Kennedy RD.
    • Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.
    • Review
    • Profile of olaparib in the treatment of advanced ovarian cancer.
    • Chase DM, Patel S, Shields K.
    • Int J Womens Health. 2016 Apr 18;8:125-9. doi: 10.2147/IJWH.S55906. eCollection 2016.
    • Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
    • Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD.
    • Oncotarget. 2016 Apr 12;7(15):20825-39. doi: 10.18632/oncotarget.7883.
    • Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    • Kaye SB.
    • Ann Oncol. 2016 Apr;27 Suppl 1:i1-i3. doi: 10.1093/annonc/mdw082.
    • PARP inhibitors in ovarian cancer.
    • Ledermann JA.
    • Ann Oncol. 2016 Apr;27 Suppl 1:i40-i44. doi: 10.1093/annonc/mdw094.
    • Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    • Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D.
    • Gynecol Oncol. 2016 Apr;141(1):57-64. doi: 10.1016/j.ygyno.2016.01.004.
    • Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
    • Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K.
    • J Cell Mol Med. 2016 Apr;20(4):581-93. doi: 10.1111/jcmm.12771. Epub 2016 Jan 22.
    • Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    • Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.
    • Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22.
    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    • Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.
    • Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
    • Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.
    • Li D, Wu QJ, Bi FF, Chen SL, Zhou YM, Zhao Y, Yang Q.
    • Am J Transl Res. 2016 Mar 15;8(3):1601-8. eCollection 2016.
    • Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
    • Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H.
    • Oncotarget. 2016 Mar 15;7(11):13153-66. doi: 10.18632/oncotarget.7549.
    • Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.
    • Lokadasan R, James FV, Narayanan G, Prabhakaran PK.
    • Ecancermedicalscience. 2016 Mar 8;10:626. doi: 10.3332/ecancer.2016.626. eCollection 2016.
    • Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    • Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.
    • Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17.
    • Veliparib for the treatment of ovarian cancer.
    • Bogliolo S, Cassani C, Dominoni M, Musacchi V, Venturini PL, Spinillo A, Ferrero S, Gardella B.
    • Expert Opin Investig Drugs. 2016 Mar;25(3):367-74. doi: 10.1517/13543784.2016.1146677. Epub 2016 Feb 16.
    • Review
    • NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer.
    • Tucker H, Charles Z, Robertson J, Adam J.
    • Lancet Oncol. 2016 Mar;17(3):277-8. doi: 10.1016/S1470-2045(16)00062-0. Epub 2016 Jan 27.
    • News
    • New treatment option for ovarian cancer: PARP inhibitors.
    • Meehan RS, Chen AP.
    • Gynecol Oncol Res Pract. 2016 Feb 26;3:3. doi: 10.1186/s40661-016-0024-7. eCollection 2016.
    • Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptormediated apoptosis.
    • De Toni EN, Ziesch A, Rizzani A, Török HP, Hocke S, Lü S, Wang SC, Hucl T, Göke B, Bruns C, Gallmeier E.
    • Oncotarget. 2016 Feb 23;7(8):9477-90. doi: 10.18632/oncotarget.7053.
    • Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    • Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S.
    • Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367.
    • Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
    • Zimmer J, Tacconi EM, Folio C, Badie S, Porru M, Klare K, Tumiati M, Markkanen E, Halder S, Ryan A, Jackson SP, Ramadan K, Kuznetsov SG, Biroccio A, Sale JE, Tarsounas M.
    • Mol Cell. 2016 Feb 4;61(3):449-60. doi: 10.1016/j.molcel.2015.12.004. Epub 2015 Dec 31.
    • BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
    • Oommen D, Yiannakis D, Jha AN.
    • Mutat Res. 2016 Feb-Mar;784-785:8-15. doi: 10.1016/j.mrfmmm.2015.11.002. Epub 2015 Nov 28.
    • Leveraging DNA repair deficiency in gynecologic oncology.
    • Walsh CS, Hodeib M.
    • Curr Opin Obstet Gynecol. 2016 Feb;28(1):24-31. doi: 10.1097/GCO.0000000000000236.
    • Review
    • PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
    • Sehouli J, Braicu EI, Chekerov R.
    • Geburtshilfe Frauenheilkd. 2016 Feb;76(2):164-169.
    • Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    • Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B.
    • Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23.
    • A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    • Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.
    • Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.
    • Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
    • Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D.
    • Cell Rep. 2016 Jan 26;14(3):429-439. doi: 10.1016/j.celrep.2015.12.046. Epub 2016 Jan 7.
    • Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
    • Nomura H, Kataoka F, Aoki D, Jinno H, Kitagawa Y, Sato Y, Womack C, Wombwell H, Hodgson D, O'Connor M, Harbron C, Yin X.
    • Cancer Biomark. 2016 Jan 18;16(1):145-52. doi: 10.3233/CBM-150550.
    • BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    • Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A.
    • Oncotarget. 2016 Jan 12;7(2):1076-83. doi: 10.18632/oncotarget.6834.
    • Olaparib.
    • Goulooze SC, Cohen AF, Rissmann R.
    • Br J Clin Pharmacol. 2016 Jan;81(1):171-3. doi: 10.1111/bcp.12761. Epub 2015 Oct 24.
    • Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    • Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.
    • Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26.
    • Olaparib for the treatment of ovarian cancer.
    • Bornstein E, Jimeno A.
    • Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714.
    • Review
    • Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    • Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.
    • Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.
    • Genomic testing and precision medicine - What does this mean for gynecologic oncology?
    • Liu J, Konstantinopoulos PA, Matulonis UA.
    • Gynecol Oncol. 2016 Jan;140(1):3-5. doi: 10.1016/j.ygyno.2015.12.001. Epub 2015 Dec 4.
    • Treatment related toxicity in BRCA1-associated epithelial ovarian cancer - is DNA repairing impairment associated with more adverse events?
    • Badora-Rybicka A, Budryk M, Nowara E, Starzyczny-Słota D.
    • Contemp Oncol (Pozn). 2016;20(5):381-384. doi: 10.5114/wo.2016.64597. Epub 2016 Dec 20.
    • Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.
    • LaFargue CJ, Tewari KS.
    • Recent Pat Biotechnol. 2016;9(2):86-101.
    • Review
    • 2016 Genetics Toolkit
    • Society of Gynecologic Oncology
    • Society of Gynecologic Oncology. 2016.

    News: New Toolkit Can Help Debunk Myths About Genetic Testing for Gynecologic Cancer. (Cure)

    • [Specific features of drug sensitivity of hereditary cancers].
    • Imyanitov EN.
    • Vopr Onkol. 2016;62(2):221-6.
    • Review, [Article in Russian]
    • High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    • Gorodnova TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, Suspitsin EN, Aleksakhina SN, Yanus GA, Togo AV, Maximov SY, Imyanitov EN.
    • Cancer Lett. 2015 Dec 28;369(2):363-7. doi: 10.1016/j.canlet.2015.08.028. Epub 2015 Sep 2.
    • PARP inhibitors in ovarian cancer.
    • Cibula D, Balmaña J.
    • Br J Cancer. 2015 Dec 15;113(S1):S1-S2. doi: 10.1038/bjc.2015.392.
    • Introductory article
    • The development of PARP inhibitors in ovarian cancer: from bench to bedside.
    • Drew Y.
    • Br J Cancer. 2015 Dec 15;113(S1):S3-S9. doi: 10.1038/bjc.2015.394.
    • Review
    • PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
    • Ledermann JA, El-Khouly F.
    • Br J Cancer. 2015 Dec 15;113(S1):S10-S16. doi: 10.1038/bjc.2015.395.
    • Review
    • UK BRCA mutation testing in patients with ovarian cancer.
    • George A.
    • Br J Cancer. 2015 Dec 15;113(S1):S17-S21. doi: 10.1038/bjc.2015.396.
    • Review
    • Individualiserad behandling vid ovarialcancer kan bli möjlig.
    • Kjölhede P, Dahm-Kähler P, Tholander B, Åvall Lundqvist E.
    • Lakartidningen. 2015 Dec 8;112. pii: DLUF.
    • Targeting tumor suppressor genes for cancer therapy.
    • Liu Y, Hu X, Han C, Wang L, Zhang X, He X, Lu X.
    • Bioessays. 2015 Dec;37(12):1277-86. doi: 10.1002/bies.201500093. Epub 2015 Oct 7.
    • Review
    • Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
    • Mahdi H, Gockley A, Esselen K, Marquard J, Nutter B, Yang B, Hinchcliff E, Horowitz N, Rose PG.
    • Gynecol Oncol. 2015 Dec;139(3):407-412. doi: 10.1016/j.ygyno.2015.07.101. Epub 2015 Jul 23.
    • Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    • Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.
    • Gynecol Oncol. 2015 Dec;139(3):568-572. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25.
    • Review
    • Outcomes of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced stage Müllerian cancer.
    • Emily Hinchcliff, Haider Mahdi, Allison Gockley, Katharine Esselen, Jessica Marquard, Benjamin Nutter, Bin Yang, Peter G. Rose, Neil Horowitz.
    • Gynecologic Oncology. 2015 Dec;139(3):589. 2015 NEAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.09.036.
    • Conference abstract
    • Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.
    • Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl CC, Helbich TH.
    • Wien Klin Wochenschr. 2015 Dec;127(23-24):981-6. doi: 10.1007/s00508-015-0880-x. Epub 2015 Nov 2.
    • Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.
    • Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT.
    • Chem Biol. 2015 Nov 19;22(11):1491-504. doi: 10.1016/j.chembiol.2015.10.003. Epub 2015 Nov 5.
    • Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
    • Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD.
    • Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13.
    • CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    • Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF.
    • Cancer Immunol Res. 2015 Nov;3(11):1257-68. doi: 10.1158/2326-6066.CIR-15-0044. Epub 2015 Jul 2.
    • Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.
    • OʼSullivan Coyne G, Chen A, Kummar S.
    • Curr Opin Oncol. 2015 Nov;27(6):475-81. doi: 10.1097/CCO.0000000000000238.
    • Review
    • PARP inhibition: A promising therapeutic target in ovarian cancer.
    • Musella A, Marchetti C, Gasparri ML, Salerno L, Casorelli A, Domenici L, Imperiale L, Ruscito I, Abdul Halim T, Palaia I, Di Donato V, Pecorini F, Monti M, Muzii L, Panici PB.
    • Cell Mol Biol (Noisy-le-grand). 2015 Oct 30;61(6):44-61.
    • Review
    • Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge.
    • Symeonides S, Gourley C.
    • Front Oncol. 2015 Oct 21;5:229. doi: 10.3389/fonc.2015.00229. eCollection 2015.
    • Successes and Challenges of PARP Inhibitors in Cancer Therapy.
    • Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R.
    • Front Oncol. 2015 Oct 14;5:222. doi: 10.3389/fonc.2015.00222. eCollection 2015.
    • FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    • Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.
    • Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17.
    • BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
    • Kan C, Zhang J.
    • Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):281-93. doi: 10.1016/j.ijrobp.2015.05.037.
    • Review
    • [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    • Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    • Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
    • Review, [Article in French]
    • Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    • Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.
    • Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.
    • PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
    • Smith HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, Straughn JM Jr.
    • Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.
    • Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    • Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.
    • Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.
    • Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.
    • Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Provencher D, Mes-Masson AM, Gotlieb WH, Witcher M.
    • BMC Med. 2015 Sep 9;13(1):217. doi: 10.1186/s12916-015-0454-9.
    • Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    • Tewari KS, Eskander RN, Monk BJ.
    • Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13.
    • Review
    • A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    • Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.
    • Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11.
    • BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
    • Gunderson CC, Moore KN.
    • Expert Rev Mol Diagn. 2015 Sep;15(9):1111-6. doi: 10.1586/14737159.2015.1078238. Epub 2015 Aug 13.
    • Review
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
    • Copur MS, Gauchan D, Brussow K, Clark D, Ramaekers R.
    • J Clin Oncol. 2015 Aug 10;33(23):2582. doi: 10.1200/JCO.2015.61.0576. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
    • Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS.
    • Biochem Biophys Res Commun. 2015 Aug 7;463(4):551-6. doi: 10.1016/j.bbrc.2015.05.083. Epub 2015 Jun 3.
    • Olaparib in the management of ovarian cancer.
    • Bixel K, Hays JL.
    • Pharmgenomics Pers Med. 2015 Aug 7;8:127-35. doi: 10.2147/PGPM.S62809. eCollection 2015.
    • Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
    • Busschots S, O'Toole S, O'Leary JJ, Stordal B.
    • Exp Cell Res. 2015 Aug 1;336(1):1-14. doi: 10.1016/j.yexcr.2014.12.001. Epub 2014 Dec 12.
    • Safety evaluation of olaparib for treating ovarian cancer.
    • Lheureux S, Bowering V, Karakasis K, Oza AM.
    • Expert Opin Drug Saf. 2015 Aug;14(8):1305-16. doi: 10.1517/14740338.2015.1045875. Epub 2015 Jun 8.
    • Review
    • Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
    • van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH.
    • Br J Cancer. 2015 Jul 28;113(3):396-402. doi: 10.1038/bjc.2015.256. Epub 2015 Jul 16.
    • Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    • Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.
    • JAMA Oncol. 2015 Jul 1;1(4):486-494. doi: 10.1001/jamaoncol.2015.1432.

    Comment

    Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer.

    • Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer.
    • Hettle R, Posnett J, Borrill J.
    • J Med Econ. [2015 Jul;]18(7):516-24. doi: 10.3111/13696998.2015.1024682. Epub 2015 Apr 7.
    • Genomic Scarring Predicts Rucaparib Activity in Ovarian Cancer.
    • [No author given]
    • ASCO Daily News. 2015 ASCO Annual Meeting. 2015 Jun 1.
    • FDA Approval — How Does it Relate to Germline Genetic Testing?
    • Laura Panos, Sara Gilvary
    • Coding Corner, Perspectives in Genetic Counseling, Volume 37, Number 2, p. 19. 2015 Qtr 2.
    • [Olaparib in ovarian cancer with BRCA mutation].
    • Pujade-Lauraine É, Combe P.
    • Bull Cancer. 2015 Jun;102(6 Suppl 1):S82-4. doi: 10.1016/S0007-4551(15)31221-2.
    • Review, [Article in French]
    • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
    • Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM.
    • Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24.
    • The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
    • Li M, Yu X.
    • Oncogene. 2015 Jun;34(26):3349-56. doi: 10.1038/onc.2014.295. Epub 2014 Sep 15.
    • Whole-genome characterization of chemoresistant ovarian cancer.
    • Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.
    • Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    • Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J.
    • Cochrane Database Syst Rev. 2015 May 20;5:CD007929. doi: 10.1002/14651858.CD007929.pub3.
    • Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
    • Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY.
    • Oncotarget. 2015 May 10;6(13):11575-84.
    • Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†.
    • Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.
    • Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.
    • Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
    • Walsh CS.
    • Gynecol Oncol. 2015 May;137(2):343-350. doi: 10.1016/j.ygyno.2015.02.017. Epub 2015 Feb 25.
    • Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
    • Jones P, Wilcoxen K, Rowley M, Toniatti C.
    • J Med Chem. 2015 Apr 23;58(8):3302-14. doi: 10.1021/jm5018237. Epub 2015 Mar 11.
    • Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
    • Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.
    • Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.
    • Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
    • Frampton JE.
    • BioDrugs. 2015 Apr;29(2):143-50. doi: 10.1007/s40259-015-0125-6.
    • Review
    • Genetic Testing and Ovarian Cancer.
    • Leigha Ann Senter-Jamieson.
    • NSGC Blog, 2015 Mar 23.
    • Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    • Gunderson CC, Moore KN.
    • Future Oncol. 2015 Mar;11(5):747-57. doi: 10.2217/fon.14.313.
    • Review
    • An update on PARP inhibitors for the treatment of cancer.
    • Benafif S, Hall M.
    • Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
    • Has the BRCA Monopoly Been Reborn?
    • Ellen T. Matloff.
    • My Gene Counsel. 2015 Feb 24.
    • Regulatory Uncertainty Causing Retesting Confusion for Patients Considering New Ovarian Cancer Rx
    • Turna Ray
    • GenomeWeb, 2015 Feb 16
    • A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
    • Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.
    • Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29.
    • The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
    • Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, Guo Z.
    • Oncotarget. 2015 Feb 10;6(4):2397-406.
    • Myriad Discusses Outlook for its Burgeoning CDx Business Following Lynparza Approval
    • Turna Ray
    • GenomeWeb, 2015 Feb 4.
    • News
    • DNA repair mutations and outcomes in ovarian cancer--letter.
    • Soslow RA.
    • Clin Cancer Res. 2015 Feb 1;21(3):658. doi: 10.1158/1078-0432.CCR-14-2436.

    Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

    Comment / Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • Familial breast cancer - targeted therapy in secondary and tertiary prevention.
    • Kast K, Rhiem K.
    • Breast Care (Basel). 2015 Feb;10(1):27-31. doi: 10.1159/000380756.
    • Olaparib: first global approval.
    • Deeks ED.
    • Drugs. 2015 Feb;75(2):231-40. doi: 10.1007/s40265-015-0345-6.
    • Review
    • Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
    • Jacot W, Theillet C, Guiu S, Lamy PJ.
    • Future Oncol. 2015 Feb;11(4):557-9. doi: 10.2217/fon.14.268.
    • Letter, Editorial / Commentary
    • Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.
    • Dubeau L.
    • Transl Cancer Res. 2015 Feb;4(1):3-13.
    • Olaparib Approved for Advanced Ovarian Cancer
    • [No author given]
    • Cancer Discovery. 2015 Jan 23. [Epub ahead of print]. doi: 10.1158/2159-8290.CD-NB2015-011
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Comment / Letter

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter

    To BRCA or Not to PALB.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Myriad Genetics' Tumor BRACAnalysis CDx Receives CE Mark
    • GenomeWeb staff reporter
    • GenomeWeb, 2015 Jan 8.
    • It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.
    • Carlucci A, D'Angiolella V.
    • Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.
    • Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis.
    • Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT.
    • Clin Cancer Res. 2015 Jan 1;21(1):211-20. doi: 10.1158/1078-0432.CCR-14-1816. Epub 2014 Oct 27.

    Comment / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.

    Reply / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.

    • Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors.
    • Lord CJ, Tutt AN, Ashworth A.
    • Annu Rev Med. [2015 Jan;]66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.
    • Review
    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • PARP Inhibition in Ovarian Cancer: State of the Science.
    • Gunderson CC, Moore KN.
    • Gynecol Oncol. 2015 Jan;136(1):8-10. doi: 10.1016/j.ygyno.2014.12.009.
    • Editorial / Commentary
    • PARP inhibitors in BRCA mutation-associated ovarian cancer.
    • Clamp A, Jayson G.
    • Lancet Oncol. 2015 Jan;16(1):10-2. doi: 10.1016/S1470-2045(14)71172-6. Epub 2014 Dec 4.
    • Comment
    • Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    • Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    • Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.

    Comment

    PARP inhibitors in BRCA mutation-associated ovarian cancer.

    • An update on PARP inhibitors-moving to the adjuvant setting.
    • Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M.
    • Nat Rev Clin Oncol. 2015 Jan;12(1):27-41. doi: 10.1038/nrclinonc.2014.163. Epub 2014 Oct 7.
    • Review
    • Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    • Duffy MJ, Walsh S, McDermott EW, Crown J.
    • Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23.
    • Review

    Comment / Introductory Journal Article

    Preface.

    • Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    • Tan DS, Kaye SB.
    • Am Soc Clin Oncol Educ Book. 2015:114-21. doi: 10.14694/EdBook_AM.2015.35.114.
    • Advances in PARP inhibitors for the treatment of breast cancer.
    • Dizdar O, Arslan C, Altundag K.
    • Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20.
    • Review
    • FDA Approves First PARP Inhibitor with Myriad's BRACAnalysis as CDx in Advanced Ovarian Cancer.
    • Turna Ray.
    • GenomeWeb, 2014 Dec 23.
    • A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
    • Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, Schuh A, Dutton SJ; 6MP Collaborative Group.
    • BMC Cancer. 2014 Dec 19;14(1):983. doi: 10.1186/1471-2407-14-983.
    • FDA Approves Myriad's BRACAnalysis CDx for Use with Ovarian Cancer Drug.
    • GenomeWeb staff reporter.
    • GenomeWeb, 2014 Dec 19.
    • FDA Approves Olaparib (Lynparza) for BRCA Ovarian Cancer.
    • Zosia Chustecka.
    • Medscape Oncology, 2014 Dec 19.
    • Olaparib Approved in Europe for BRCA Ovarian Cancer.
    • Chustecka Z.
    • Medscape. 2014 Dec 18.
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy.
    • Zhang S, Yuan Y, Hao D.
    • PLoS One. 2014 Dec 1;9(12):e113169. doi: 10.1371/journal.pone.0113169. eCollection 2014.
    • Myriad, AbbVie Expand Tumor BRACAnalysis CDx Collaboration.
    • [No author given]
    • Clinical OMICs. 1(14):5. 2014 Nov 19.
    • Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
    • Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM.
    • J Surg Oncol. 2014 Nov;110(6):661-5. doi: 10.1002/jso.23688. Epub 2014 Jun 24.
    • European OK for Olaparib in Ovarian Cancer.
    • Chustecka Z.
    • Medscape. 2014 Oct 24.
    • BRCA1/2 Mutation Status Is an Independent Factor of Improved Survival for Advanced (Stage III-IV) Ovarian Cancer.
    • Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R.
    • Int J Gynecol Cancer. 2014 Oct;24(8):1395-400. doi: 10.1097/IGC.0000000000000247.
    • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
    • Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.
    • Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.
    • Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
    • Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zhabina AS, Gorodnova TV, Komarov YI, Bogdanov AA, Sokolenko AP, Imyanitov EN.
    • Med Oncol. 2014 Oct;31(10):199. doi: 10.1007/s12032-014-0199-x. Epub 2014 Sep 4.
    • Maintenance therapy in ovarian cancer.
    • Khalique S, Hook JM, Ledermann JA.
    • Curr Opin Oncol. 2014 Sep;26(5):521-8. doi: 10.1097/CCO.0000000000000110.
    • Review
    • PARP inhibition and synthetic lethality in ovarian cancer.
    • Eskander RN, Tewari KS.
    • Expert Rev Clin Pharmacol. 2014 Sep;7(5):613-22. doi: 10.1586/17512433.2014.930662. Epub 2014 Jul 2.
    • Review
    • Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
    • Yamamoto KN, Hirota K, Takeda S, Haeno H.
    • PLoS One. 2014 Aug 26;9(8):e105724. doi: 10.1371/journal.pone.0105724. eCollection 2014.
    • Myriad Awaits BRACAnalysis CDx Approval as it Works to Move Hereditary Cancer Testing to MyRisk
    • Molika Ashford
    • GenomeWeb, 2014 Aug 13
    • News
    • Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
    • Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.
    • Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.
    • Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
    • Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.
    • Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
    • An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
    • Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.
    • Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.
    • Made-to-measure medicine: BRCA and gynaecological cancer.
    • Foulkes WD.
    • Lancet Oncol. 2014 Jul;15(8):783-5. doi: 10.1016/S1470-2045(14)70246-3. Epub 2014 May 31.
    • Commentary
    • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U.
    • Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.
    • FDA Panel Votes Against Accelerated Approval for Olaparib.
    • Hand L.
    • Medscape. 2014 Jun 26.
    • Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    • Watkins JA, Irshad S, Grigoriadis A, Tutt AN.
    • Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.
    • Targeted Drug Combo Improves Outcomes in Ovarian Cancer.
    • Nelson R.
    • Medscape. 2014 Jun 1.
    • The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
    • Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Adams S.
    • Gynecol Oncol. 2014 Jun;133(3):584-590. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.
    • Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    • Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.
    • Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.
    • Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    • Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.
    • Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11.
    • Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
    • Sun CK, Zhang F, Xiang T, Chen Q, Pandita TK, Huang Y, Hu MC, Yang Q.
    • Oncotarget. 2014 May 30;5(10):3375-85.
    • Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses.
    • Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
    • J Natl Cancer Inst. 2014 May 19;106(6). pii: dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.
    • On the road to PARPi-platin.
    • Bookman MA.
    • J Natl Cancer Inst. 2014 May 19;106(6):dju119. doi: 10.1093/jnci/dju119. Print 2014 Jun.
    • What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer.
    • Thomas Herzog, Elizabeth M. Swisher, Kristin K. Zorn.
    • Medscape Education Oncology, 2014 May 6.
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
    • Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F.
    • Ann Surg Oncol. 2014 May;21(5):1468-73. doi: 10.1245/s10434-013-3277-y. Epub 2013 Oct 1.
    • PARP inhibitors in ovarian cancer: Current status and future promise.
    • Liu JF, Konstantinopoulos PA, Matulonis UA.
    • Gynecol Oncol. 2014 May;133(2):362-369. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4.
    • Review
    • Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
    • Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM.
    • J Biol Chem. 2014 Mar 28;289(13):9247-53. doi: 10.1074/jbc.M114.551143. Epub 2014 Feb 19.
    • Veliparib Active in BRCA-Positive Ovarian Cancer.
    • Fran Lowry.
    • Medscape Medical News from the Society of Gynecologic Oncology (SGO) 45th Annual Meeting on Women's Cancer, 2014 Mar 26.
    • Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
    • Wiedemeyer WR, Beach JA, Karlan BY.
    • Front Oncol. 2014 Mar 3;4:34. doi: 10.3389/fonc.2014.00034. eCollection 2014.
    • Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
    • Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC.
    • Mol Cancer Res. 2014 Mar;12(3):381-93. doi: 10.1158/1541-7786.MCR-13-0480. Epub 2014 Jan 10.
    • Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
    • O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    • Front Oncol. 2014 Feb 28;4:42. eCollection 2014.
    • BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
    • Burgess M, Puhalla S.
    • Front Oncol. 2014 Feb 27;4:19. eCollection 2014.
    • Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
    • Bouwman P, Jonkers J.
    • Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22.
    • Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    • Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.
    • Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: PALB2 and Ovarian Cancer

    Comment, Letter

    DNA repair mutations and outcomes in ovarian cancer--letter.

    Reply, Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • 'BRCAness' and its implications for platinum action in gynecologic cancer.
    • Muggia F, Safra T.
    • Anticancer Res. 2014 Feb;34(2):551-6.
    • PARP inhibitors for anticancer therapy.
    • Curtin N.
    • Biochem Soc Trans. 2014 Feb;42(1):82-8. doi: 10.1042/BST20130187.
    • [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    • Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F.
    • Bull Cancer. 2014 Feb;101(2):167-74. doi: 10.1684/bdc.2014.1888.
    • Review, [Article in French]
    • Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells.
    • Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA.
    • Oncol Rep. 2014 Feb;31(2):551-6. doi: 10.3892/or.2013.2902. Epub 2013 Dec 5.
    • Poly (ADP-ribose) polymerase 1 transcriptional regulation: a novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer.
    • Li D, Bi FF, Cao JM, Cao C, Li CY, Liu B, Yang Q.
    • Oncotarget. 2014 Jan 15;5(1):291-7.
    • Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity.
    • Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.
    • Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • Targeting the BRCA1/2 Tumor Suppressors.
    • Rosen EM, Pishvaian MJ.
    • Curr Drug Targets. 2014 Jan;15(1):17-31.
    • Review
    • Clinical implications of using molecular diagnostics for ovarian cancers.
    • Kohn EC, Romano S, Lee JM.
    • Ann Oncol. 2013 Dec;24 Suppl 10:x22-26. doi: 10.1093/annonc/mdt464.
    • Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    • Curtin NJ, Szabo C.
    • Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29.
    • Appraising iniparib, the PARP inhibitor that never was--what must we learn?
    • Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS.
    • Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. doi: 10.1038/nrclinonc.2013.177. Epub 2013 Oct 15.
    • Review
    • Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    • Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD.
    • Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94. doi: 10.1073/pnas.1314302110. Epub 2013 Nov 11.
    • miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition.
    • Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G.
    • J Natl Cancer Inst. 2013 Nov 20;105(22):1750-8. doi: 10.1093/jnci/djt302. Epub 2013 Oct 29.
    • PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.
    • Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G.
    • Front Oncol. 2013 Nov 14;3:279. doi: 10.3389/fonc.2013.00279. eCollection 2013.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    • Pothuri B.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307.
    • Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
    • Lord CJ, Ashworth A.
    • Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7.
    • Review
    • Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    • Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.
    • Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-17046. Epub 2013 Oct 1.
    • Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
    • Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB.
    • Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.
    • The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
    • Reinbolt RE, Hays JL.
    • Front Oncol. 2013 Oct 1;3:237. doi: 10.3389/fonc.2013.00237.
    • Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.
    • Shaw HM, Hall M.
    • Onco Targets Ther. 2013 Sep 3;6:1197-206. doi: 10.2147/OTT.S30748.
    • A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.
    • Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j.ejca.2013.05.020. Epub 2013 Jun 27.
    • Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
    • Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
    • Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.
    • Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    • Chen Y, Zhang L, Hao Q.
    • Arch Gynecol Obstet. 2013 Aug;288(2):367-74. doi: 10.1007/s00404-013-2856-2. Epub 2013 Apr 26.
    • Review
    • Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    • Gan A, Green AR, Nolan CC, Martin S, Deen S.
    • Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.
    • Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

    Commentary:

    PARP inhibitors: pitfalls and promises.

    • Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
    • Croset A, Cordelières FP, Berthault N, Buhler C, Sun JS, Quanz M, Dutreix M.
    • Nucleic Acids Res. 2013 Aug;41(15):7344-55. doi: 10.1093/nar/gkt522. Epub 2013 Jun 12.
    • RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
    • Lok BH, Carley AC, Tchang B, Powell SN.
    • Oncogene. 2013 Jul 25;32(30):3552-8. doi: 10.1038/onc.2012.391. Epub 2012 Sep 10.
    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
    • Galic V, Coleman RL, Herzog TJ.
    • Curr Cancer Drug Targets. 2013 Jul;13(6):698-707.
    • Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT +) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062).
    • Lee J, Hays J, Noonan A, Annunziata C, Minasian L, Zujewski J, Houston N, Hearn J, Yu M, Kohn E.
    • Gynecologic Oncology. 2013 Jul;130(1):e11. 44th Annual Meeting of the Society of Gynecologic Oncology. doi: 10.1016/j.ygyno.2013.04.083.
    • Conference abstract
    • PARP Inhibitor Research Update.
    • Susan Domchek.
    • FORCE. Be Empowered Webinars. 2013 Jun 27.
    • BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.
    • Mayor P, Gay LM, Lele S, Elvin JA.
    • Gynecol Oncol Rep. 2017 Jun 21;21:57-60. doi: 10.1016/j.gore.2017.06.010. eCollection 2017 Aug.
    • ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status.
    • Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.
    • Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.
    • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    • Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.
    • Int J Gynecol Cancer. 2013 Jun;23(5):846-52. doi: 10.1097/IGC.0b013e31829527bd.
    • Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
    • Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.
    • Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.
    • BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
    • Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT.
    • Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31.
    • BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
    • Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.
    • Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

    Research news: Can BRCA Expression Predict Response to Chemotherapy? (Medscape)

    • Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
    • Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB.
    • Eur J Cancer. 2013 Apr;49(6):1246-53. doi: 10.1016/j.ejca.2012.11.016. Epub 2012 Dec 19.
    • Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer.
    • Bi FF, Li D, Yang Q.
    • BMC Cancer. 2013 Feb 26;13:90. doi: 10.1186/1471-2407-13-90.
    • Genetics of Susceptibility to Sporadic Ovarian Cancer.
    • Katabathina VS, Prasad SR.
    • eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. doi: 10.1002/9780470015902.a0023853. 2013 Feb.
    • Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
    • Wong HH, Parkinson C, Ledermann JA, Brenton JD, Merger M, Shaw A, Patterson A, Shafi M, Earl HM.
    • Gynecol Oncol Case Rep. 2013 Jan 1;3:7-10. doi: 10.1016/j.gynor.2012.10.003.
    • Major clinical research advances in gynecologic cancer in 2012.
    • Suh DH, Kim JW, Kim K, Kim HJ, Lee KH.
    • J Gynecol Oncol. 2013 Jan;24(1):66-82. doi: 10.3802/jgo.2013.24.1.66. Epub 2013 Jan 8.
    • Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
    • Elit L, Hirte H.
    • Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26.

Continue to Older References